var title_f43_19_44336="PDR neovascularization retin vessels";
var content_f43_19_44336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proliferative diabetic retinopathy displaying severe neovascularization along the superior arcade (NVE): Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color fundus photograph of proliferative diabetic retinopathy displaying severe neovascularization along the superior arcade (NVE).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44336=[""].join("\n");
var outline_f43_19_44336=null;
var title_f43_19_44337="Jejunal leiomyoma Gross";
var content_f43_19_44337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jejunal leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen of a large jejunal leiomyoma that caused a small bowel obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44337=[""].join("\n");
var outline_f43_19_44337=null;
var title_f43_19_44338="Diatrizoate meglumine and iodipamide meglumine: Drug information";
var content_f43_19_44338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diatrizoate meglumine and iodipamide meglumine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/49/27411?source=see_link\">",
"    see \"Diatrizoate meglumine and iodipamide meglumine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sinografin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic, Low Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5947833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hysterosalpingography: Intrauterine: Usual dose: 3-4 mL administered in fractional doses of ~1 mL; may give additional 3-4 mL to visualize tubes; total dosage range: 1.5-10 mL",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [for intrauterine instillation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sinografin&reg;: Diatrizoate meglumine 527 mg and iodipamide meglumine 268 mg per mL (10 mL) [provides organically-bound iodine 380 mg/mL; contains edetate disodium, sodium 0.91 mg (0.04 mEq)/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5947834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For intrauterine use only; administer in fractional doses of ~1 mL",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hysterosalpingography",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5978076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5947826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Bradycardia (rare), cardiac arrest (rare), hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Chills, dizziness, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, abdominal tenderness, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactoid reactions, hypersensitivity reactions (including sweating, flushing, pruritus, urticaria, rash, arthralgia, respiratory distress, and circulatory collapse)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; during or within 6 months following pregnancy termination; infection of external genitalia or genital tract; during menstrual period; within 30 days of curettage or conization",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5947822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reactions: Use extreme caution with history of previous reaction to contrast dye or iodine-based contrast media or asthma. Severe, potentially life-threatening reactions and delayed reactions may occur. Pretreatment with corticosteroids (eg, prednisone) and antihistamines (eg, diphenhydramine) may be beneficial to decrease the frequency/severity of allergic reactions in &ldquo;at risk&rdquo; patients. Equipment for resuscitation and trained personnel experienced in handling emergencies should be immediately available. Monitor closely after injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Uterine cancer: Use with caution in patients with uterine or uterine tube cancer; procedure may cause dispersion of cancer cells.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F159610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The procedure for which this product is indicated is contraindicated during or within 6 months of pregnancy. Diatrizoate meglumine crosses the placenta and enters the fetal circulation. Also refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F159611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diatrizoate meglumine and iodipamide meglumine have been found in breast milk following intravascular administration.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9730004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sinografin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     52.7-26.8% (10 mL): $64.55",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8603 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44338=[""].join("\n");
var outline_f43_19_44338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159614\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159617\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5947833\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796047\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796048\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159606\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159603\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5947834\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159607\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5978076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5947826\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159609\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5947822\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299177\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219800\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159610\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159615\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159611\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9730004\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323109\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8603\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8603|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/49/27411?source=related_link\">",
"      Diatrizoate meglumine and iodipamide meglumine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_19_44339="Multilevel spinal stenosis";
var content_f43_19_44339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multilevel spinal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted sagittal MRI of the lower thoracic, lumbar, and sacral spine demonstrates spinal stenosis at multiple levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Seward Rutkove, MD and Andrew Tarulli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44339=[""].join("\n");
var outline_f43_19_44339=null;
var title_f43_19_44340="Fluticasone (topical): Drug information";
var content_f43_19_44340=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluticasone (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/54/15204?source=see_link\">",
"    see \"Fluticasone (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/7/27764?source=see_link\">",
"    see \"Fluticasone (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9349371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cutivate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9349372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cutivate&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9349375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9349442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corticosteroid-responsive dermatoses:",
"     </b>",
"     Topical: Cream, lotion, ointment: Apply sparingly to affected area twice daily. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"     Topical: Cream, lotion: Apply sparingly to affected area once or twice daily. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9349441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/7/27764?source=see_link\">",
"      see \"Fluticasone (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corticosteroid-responsive dermatoses:",
"     </b>",
"     Topical: Children &ge;3 months: Cream: Apply sparingly to affected area twice daily. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;3 months: Cream: Apply sparingly to affected area 1-2 times/day. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;1 year: Lotion: Apply sparingly to affected area once daily.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9349443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as propionate: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutivate&reg;: 0.05% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as propionate: 0.05% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutivate&reg;: 0.05% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as propionate: 0.005% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutivate&reg;: 0.005% (30 g, 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9349374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9349444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Apply sparingly in a thin film. Rub in lightly. Unless otherwise directed by healthcare professional, do not use with occlusive dressing; do not use on children&rsquo;s skin covered by diapers or plastic pants.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F242557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Relief of inflammation and pruritus associated with corticosteroid-responsive dermatoses; atopic dermatitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9349367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cutivate&reg; may be confused with Ultravate&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively, [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9349425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Telangiectasia (children 2% to 5%), pruritus (3%), skin irritation (3%), exacerbation of eczema (2%), rash (erythematous; children 2%), dryness (1%), eczema infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness of fingers (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acneiform eruptions, atrophy, blurred vision, Cushing syndrome, dermatitis, edema, folliculitis, hemorrhage, hyperglycemia, immunosuppression, leukopenia, secondary infection, sepsis, skin discoloration, thrombocytopenia, urticaria, viral warts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported with other topical corticosteroids (in decreasing order of occurrence): Hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin atrophy, striae, hypertrichosis, miliaria, pustular psoriasis from chronic plaque psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9349381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Do not use if infection is present at treatment site, in the presence of skin atrophy, or for the treatment of rosacea or perioral dermatitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9349382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lotion and cream: Contain imidurea, an excipient; imidurea releases trace amounts of formaldehyde which may cause irritation or allergic sensitization upon contact with skin. Discontinue lotion if irritation occurs and institute appropriate therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9349429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9349428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9349376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9349377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with systemic corticosteroids in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9349379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9349380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of fluticasone are absorbed following topical administration to produce detectable amounts in breast milk. Hypertension in the nursing infant has been reported following corticosteroid ointment applied to the nipples. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9349453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cutivate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $135.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Fluticasone Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $34.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Cutivate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (120 mL): $888.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Fluticasone Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 mL): $389.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Cutivate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (30 g): $83.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Fluticasone Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (30 g): $34.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9349446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency; possible eosinophilic conditions (including Churg-Strauss syndrome)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Allevisone (TW);",
"     </li>",
"     <li>",
"      Cutivat (DK);",
"     </li>",
"     <li>",
"      Cutivate (AR, AT, BB, BE, BG, BM, BS, CH, CL, CR, CZ, DO, EC, EE, GB, GT, GY, HK, HN, JM, KP, MY, NL, PA, PE, PH, PK, PL, PR, PT, PY, RU, SG, SV, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Flixovate (FR);",
"     </li>",
"     <li>",
"      Flutivate (BR, CN, DE, NO);",
"     </li>",
"     <li>",
"      Futisone (TW);",
"     </li>",
"     <li>",
"      Medicort (ID);",
"     </li>",
"     <li>",
"      Zoflut (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9349435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity; has a weak HPA inhibitory potency when applied topically, which gives the drug a high therapeutic index. The mechanism of action for all topical corticosteroids is believed to be a combination of three important properties: anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9349437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 5% (increased with inflammation)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44340/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9137 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44340=[""].join("\n");
var outline_f43_19_44340=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349371\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349372\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349375\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349442\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349441\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349443\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242556\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349374\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349444\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242557\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349367\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349425\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349381\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349382\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349429\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349428\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349376\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349377\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349379\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349380\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349453\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349446\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961909\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349435\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349437\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9137\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9137|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/3/30773?source=related_link\">",
"      Fluticasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/5/28756?source=related_link\">",
"      Fluticasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/45/32468?source=related_link\">",
"      Fluticasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26120?source=related_link\">",
"      Fluticasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/33/12822?source=related_link\">",
"      Fluticasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/29/25047?source=related_link\">",
"      Fluticasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/54/15204?source=related_link\">",
"      Fluticasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/7/27764?source=related_link\">",
"      Fluticasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_19_44341="Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency";
var content_f43_19_44341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44341/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44341/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44341/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44341/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44341/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44341/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44341/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/19/44341/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"mobipreview.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs) (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"mobipreview.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly, and the primary features of those defects that affect muscle are muscle cramps, exercise intolerance, easy fatigability, and progressive weakness.",
"   </p>",
"   <p>",
"    This topic will review phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency (glycogen storage disease X, GSD X). An overview of disorders of glycogen metabolism is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHOSPHOGLYCERATE KINASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphoglycerate kinase (PGK) catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate; one molecule of ATP is generated in the process. Deficiency of PGK (MIM #311800) results in three different clinical presentations (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphoglycerate kinase 1 is a monomeric enzyme encoded by a gene on chromosome Xq13 (PGK1). Thus, inheritance occurs as an X-linked recessive trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/1\">",
"     1",
"    </a>",
"    ]. An isoform (PGK2) is expressed in spermatogenic cells. A variety of missense and",
"1ff8",
" nonsense mutations of PGK1 have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/2\">",
"     2",
"    </a>",
"    ]. No clear genotype-phenotype association has been identified, except that there appears to be clustering of all myopathic mutations in the C terminal domain near the substrate binding pocket [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of onset for PGK deficiency is variable. PGK deficiency may present as either isolated or associated involvement of three tissues (erythrocytes, the central nervous system, and skeletal muscle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system (CNS) dysfunction with seizures and intellectual disability (mental retardation) that is associated with nonspherocytic hemolytic anemia. The PGK-Barcelona mutation (a c.140T&rarr;A substitution) results in loss of enzyme stability and causes progressive neurologic impairment with associated chronic hemolytic anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients with hemolytic anemia and CNS involvement usually lack evidence of clinical myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. However, recurrent myoglobinuria was reported in a 33-year-old man with intellectual disability and reduced PGK1 activity in his muscles and erythrocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      Hereditary nonspherocytic hemolytic anemia without CNS involvement. Heterozygous females may have variable degrees of enzyme activity and may show some signs of hemolytic anemia.",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      Isolated myopathy with exercise intolerance, myoglobinuria, cramps, and slowly progressive weakness. Patients with myoglobinuria usually do not develop hemolytic anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/3,13\">",
"       3,13",
"      </a>",
"      ], but concurrent hemolysis and rhabdomyolysis with associated hemoglobinuria and myoglobinuria may occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/14\">",
"       14",
"      </a>",
"      ]. Only nine patients with isolated myopathy have been reported thus far [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/3\">",
"       3",
"      </a>",
"      ]. In addition, exertional myoglobinuria and severe parkinsonism, but no hemolytic anemia, was reported in a 25-year-old man with the p.T378P mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/15\">",
"       15",
"      </a>",
"      ]. In patients with myopathy, the resting serum creatine kinase (CK) level is usually elevated, although this feature is not uniformly observed. Muscle biopsy may reveal glycogen accumulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1478332\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PGK deficiency is the only X-linked form of hereditary non-spherocytic hemolytic anemia, which differentiates it from other similar defects. The diagnosis is made by demonstrating a deficiency of PGK1 enzymatic activity in muscle biopsy tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythrocytes. Molecular analysis may detect a mutation in the PGK1 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/16\">",
"     16",
"    </a>",
"    ]. Increased tetraglucoside excretion was documented in the urine of patients with PGK1 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/17\">",
"     17",
"    </a>",
"    ]. The authors have proposed measurement of urine tetraglucoside excretion as a screening test for possible glycogenosis.",
"   </p>",
"   <p>",
"    The myopathic form typically presents in childhood and is difficult to distinguish clinically from GSD V (muscle phosphorylase deficiency) and GSD VII (muscle phosphofructokinase deficiency) without muscle biopsy and biochemical determinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23928?source=see_link\">",
"     \"Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28596?source=see_link\">",
"     \"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzyme replacement therapy for PGK deficiency is not available. However, hematopoietic cell transplantation may be an option. Allogeneic bone marrow transplant for PGK deficiency was performed in a three-year-old child with hemolytic anemia and progressive neurologic involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/19\">",
"     19",
"    </a>",
"    ]. The patient continued to experience significant improvement four years posttransplant, with no hemolytic episodes and amelioration of his neurologic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHOSPHOGLYCERATE MUTASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphoglycerate mutase (PGAM) catalyzes the conversion of 3-phosphoglycerate to 2-phosphoglycerate. Deficiency of the muscle isoform of the enzyme (PGAM2) (MIM # 261670) results in muscle disease (glycogen storage disease X, GSD X) that becomes apparent in childhood or adolescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle form of phosphoglycerate mutase (PGAM-M) maps to chromosome 7p13-p12.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/20\">",
"     20",
"    </a>",
"    ]. Human PGAM is a dimer consisting of different amounts of MM isozyme, brain BB isozyme, and the intermediate hybrid MB isozyme. The gene for the PGAM-B subunit maps to chromosome 10q25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inheritance is autosomal recessive. Various distinct point mutations have been described in studies of African-American, African, and Caucasian patients with PGAM-M deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. Symptomatic heterozygotes have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;PGAM deficiency presents primarily with dynamic symptoms such as exercise intolerance, muscle aches, cramps, and myoglobinuria following intense physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/4,30\">",
"     4,30",
"    </a>",
"    ]. Symptoms may begin in childhood or adolescence and mimic the manifestations of GSD V (muscle phosphorylase deficiency, McArdle disease). However, in contrast to patients with McArdle disease, a second-wind phenomenon does not occur, and infusion of lipid and lactate does not improve exercise capacity [",
"    <a 1ff8 c href=\"mobipreview.htm?43/19/44341/abstract/31\" lass=\"abstract\">",
"     31",
"    </a>",
"    ].Between attacks, serum creatine kinase levels may be elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20307191\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy shows mild glycogen storage in most cases. Subsarcolemmal tubular aggregates have been detected in type 2 fibers in muscle biopsies from patients with PGAM deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/23,32\">",
"     23,32",
"    </a>",
"    ]; albeit nonspecific, this pathologic finding in a patient with exercise-induced cramps and recurrent myoglobinuria is highly suggestive of PGAM deficiency. Muscle PGAM activity is decreased on enzyme assay, and molecular analysis may reveal a mutation in the PGAM gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective therapy is available for PGAM deficiency. A single patient with PGAM deficiency became asymptomatic on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    treatment and had a forearm ischemic test without exercise-induced contractures; this patient had tubular aggregates and increased Ca2+-adenosine triphosphatase and calcium content in muscle tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44341/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1478362\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inborn errors of glycogen metabolism include the inherited glycogen storage diseases (",
"      <a class=\"graphic graphic_table graphicRef54417 \" href=\"mobipreview.htm?37/36/38477\">",
"       table 1",
"      </a>",
"      ). The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance, easy fatigability, and progressive weakness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40500?source=see_link&amp;anchor=H1#H1\">",
"       \"Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency\", section on 'Introduction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phosphoglycerate kinase (PGK) deficiency can result in one of three or combined presentations: Central nervous system dysfunction with seizures and intellectual disability (mental retardation) that is associated with nonspherocytic hemolytic anemia, hereditary nonspherocytic hemolytic anemia without CNS involvement, or isolated myopathy with exercise intolerance, myoglobinuria, cramps, and slowly progressive weakness. The diagnosis is confirmed by demonstrating a deficiency of PGK1 enzymatic activity in muscle biopsy tissue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erythrocytes. Molecular analysis may detect a mutation in the PGK1 gene. Enzyme replacement therapy for PGK deficiency is not available. However, hematopoietic cell transplantation may be an option. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Phosphoglycerate kinase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phosphoglycerate mutase (PGAM) deficiency (glycogen storage disease X, GSD X) presents primarily with dynamic symptoms such as exercise intolerance, muscle aches, cramps, and myoglobinuria following intense physical activity. The diagnosis is confirmed by demonstrating a deficiency of PGAM enzymatic activity in muscle biopsy tissue, and molecular analysis may reveal a mutation in the PGAM gene. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Phosphoglycerate mutase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/1\">",
"      Meera Khan P, Westerveld A, Grzeschik KH, et al. X-linkage of human phosphoglycerate kinase confirmed in man-mouse and man-Chinese hamster somatic cell hybrids. Am J Hum Genet 1971; 23:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/2\">",
"      Miwa S, Fujii H. Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Am J Hematol 1996; 51:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/3\">",
"      Spiegel R, Gomez EA, Akman HO, et al. Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord 2009; 19:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/4\">",
"      DiMauro S, Miranda AF, Khan S, et al. Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy. Science 1981; 212:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/5\">",
"      Sugie H, Sugie Y, Nishida M, et al. Recurrent myoglobinuria in a child with mental retardation: phosphoglycerate kinase deficiency. J Child Neurol 1989; 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/6\">",
"      Beutler E. PGK deficiency. Br J Haematol 2007; 136:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/7\">",
"      Ram&iacute;rez-Bajo MJ, Repiso A, la Ossa PP, et al. Enzymatic and metabolic characterization of the phosphoglycerate kinase deficiency associated with chronic hemolytic anemia caused by the PGK-Barcelona mutation. Blood Cells Mol Dis 2011; 46:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/8\">",
"      Noel N, Flanagan JM, Flanagan J, et al. Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol 2006; 132:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/9\">",
"      Flanagan JM, Rhodes M, Wilson M, Beutler E. The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol 2006; 134:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/10\">",
"      Valentine WN, Hsieh HS, Paglia DE, et al. Hereditary hemolytic anemia associated with phosphoglycerate kinase deficiency in erythrocytes and leukocytes. A probable X-chromosome-linked syndrome. N Engl J Med 1969; 280:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/11\">",
"      DiMauro S, Dalakas M, Miranda AF. Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria. Ann Neurol 1983; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/12\">",
"      Shirakawa K, Takahashi Y, Miyajima H. Intronic mutation in the PGK1 gene may cause recurrent myoglobinuria by aberrant splicing. Neurology 2006; 66:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/13\">",
"      Rosa R, George C, Fardeau M, et al. A new case of phosphoglycerate kinase deficiency: PGK Creteil",
"1ff8",
" associated with rhabdomyolysis and lacking hemolytic anemia. Blood 1982; 60:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/14\">",
"      Morimoto A, Ueda I, Hirashima Y, et al. A novel missense mutation (1060G --&gt; C) in the phosphoglycerate kinase gene in a Japanese boy with chronic haemolytic anaemia, developmental delay and rhabdomyolysis. Br J Haematol 2003; 122:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/15\">",
"      Sotiriou E, Greene P, Krishna S, et al. Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve 2010; 41:707.",
"     </a>",
"    </li>",
"    <li>",
"     PGK1 full gene sequencing through Emory Genetics Laboratory: file://genetics.emory.edu/egl/tests/?testid=1481 (Accessed on December 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/17\">",
"      Morava E, Wortmann SB, van Essen HZ, et al. Biochemical characteristics and increased tetraglucoside excretion in patients with phosphorylase kinase deficiency. J Inherit Metab Dis 2005; 28:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/18\">",
"      Aasly J, van Diggelen OP, Boer AM, Br&oslash;nstad G. Phosphoglycerate kinase deficiency in two brothers with McArdle-like clinical symptoms. Eur J Neurol 2000; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/19\">",
"      Rhodes M, Ashford L, Manes B, et al. Bone marrow transplantation in phosphoglycerate kinase (PGK) deficiency. Br J Haematol 2011; 152:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/20\">",
"      Edwards YH, Sakoda S, Schon E, Povey S. The gene for human muscle-specific phosphoglycerate mutase, PGAM2, mapped to chromosome 7 by polymerase chain reaction. Genomics 1989; 5:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/21\">",
"      Tsujino S, Sakoda S, Mizuno R, et al. Structure of the gene encoding the muscle-specific subunit of human phosphoglycerate mutase. J Biol Chem 1989; 264:15334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/22\">",
"      Junien C, Despoisse S, Turleau C, et al. Assignment of phosphoglycerate mutase (PGAMA) to human chromosome 10. Regional mapping of GOT1 and PGAMA to subbands 10q26.1 (or q25.3). Ann Genet 1982; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/23\">",
"      Naini A, Toscano A, Musumeci O, et al. Muscle phosphoglycerate mutase deficiency revisited. Arch Neurol 2009; 66:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/24\">",
"      Tsujino S, Shanske S, Sakoda S, et al. The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. Am J Hum Genet 1993; 52:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/25\">",
"      Tsujino S, Shanske S, Sakoda S, et al. Molecular genetic studies in muscle phosphoglycerate mutase (PGAM-M) deficiency. Muscle Nerve 1995; 3:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/26\">",
"      Toscano A, Tsujino S, Vita G, et al. Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred. Muscle Nerve 1996; 19:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/27\">",
"      Tonin P, Bruno C, Cassandrini D, et al. Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene. Neuromuscul Disord 2009; 19:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/28\">",
"      Hadjigeorgiou GM, Kawashima N, Bruno C, et al. Manifesting heterozygotes in a Japanese family with a novel mutation in the muscle-specific phosphoglycerate mutase (PGAM-M) gene. Neuromuscul Disord 1999; 9:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/29\">",
"      Joshi PR, Knape M, Zierz S, Deschauer M. Phosphoglycerate mutase deficiency: case report of a manifesting heterozygote with a novel E154K mutation and very late onset. Acta Neuropathol 2009; 117:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/30\">",
"      Servidei S, DiMauro S. Disorders of glycogen metabolism of muscle. Neurol Clin 1989; 7:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/31\">",
"      Vissing J, Quistorff B, Haller RG. Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol 2005; 62:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/32\">",
"      Oh SJ, Park KS, Ryan HF Jr, et al. Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency. Muscle Nerve 2006; 34:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44341/abstract/33\">",
"      Vissing J, Schmalbruch H, Haller RG, Clausen T. Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene. Ann Neurol 1999; 46:274.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2911 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44341=[""].join("\n");
var outline_f43_19_44341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1478362\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHOSPHOGLYCERATE KINASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1478332\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHOSPHOGLYCERATE MUTASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20307191\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a 1065 class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478362\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2911\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2911|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2911|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23928?source=related_link\">",
"      Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40500?source=related_link\">",
"      Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28596?source=related_link\">",
"      Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_19_44342="Tocilizumab: Drug information";
var content_f43_19_44342=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tocilizumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/63/1013?source=see_link\">",
"    see \"Tocilizumab: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/14/9446?source=see_link\">",
"    see \"Tocilizumab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9773700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9756027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actemra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10819878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Actemra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9773705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Interleukin-6 Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9773954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     I.V.: Initial: 4 mg/kg every 4 weeks; may be increased to 8 mg/kg based on clinical response (maximum dose: 800 mg).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12780726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/14/9446?source=see_link\">",
"      see \"Tocilizumab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Systemic juvenile idiopathic arthritis (SJIA):",
"     </b>",
"     Children &ge;2 years: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dose adjustment should not be made based solely on a single-visit body weight measurement due to fluctuations in body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;30 kg: 12 mg/kg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;30 kg: 8 mg/kg every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9773955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild renal impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe renal impairment: No dosage adjustment provided in  the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9773956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in patients with active hepatic disease or hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9773957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypersensitivity (anaphylaxis or other clinically-significant hypersensitivity reaction):",
"     </b>",
"     Stop infusion and discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Infection (serious infection, opportunistic infection or sepsis):",
"     </b>",
"     Interrupt treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Rheumatoid arthritis (RA):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Liver enzyme abnormalities:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;1 to 3 x ULN: Adjust concomitant DMARDs as appropriate; for persistent increases &gt;1 to 3 x ULN, reduce dose to 4 mg/kg or interrupt until ALT/AST have normalized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;3 to 5 x ULN: Interrupt until ALT/AST &lt;3 x ULN, then resume at 4 mg/kg. For persistent increases &gt;3 x ULN, discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;5 x ULN: Discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Low absolute neutrophil counts (ANC):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ANC &gt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Maintain dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ANC 500-1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt therapy; when ANC &gt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , resume tocilizumab at 4 mg/kg. May increase to 8 mg/kg as clinically appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Low platelet counts:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets 50,000-100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt therapy; when platelet count is &gt;100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , resume tocilizumab at 4 mg/kg; may increase to 8 mg/kg as clinically appropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets &lt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Systemic juvenile idiopathic arthritis (SJIA):",
"     </b>",
"     Dose reductions have not been studied; however, dose interruptions are recommended for liver enzyme abnormalities, low neutrophil counts, and low platelets similar to recommendations provided for rheumatoid arthritis. In addition, consider interrupting or discontinuing concomitant methotrexate and/or other medications.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9773963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actemra&reg;: 20 mg/mL (4 mL, 10 mL, 20 mL) [contains polysorbate 80, sucrose 50 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9773703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9773701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM197463.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM197463.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9773959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Allow diluted solution for infusion to reach room temperature prior to administration; infuse over 60 minutes using a dedicated I.V. line. Do not infuse other agents through same I.V. line. Do not administer I.V. push or I.V. bolus. Do not use if opaque particles or discoloration is visible.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9773707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderately- to severely-active rheumatoid arthritis in adult patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs) (as monotherapy or in combination with methotrexate or other nonbiological DMARDs); treatment of active systemic juvenile idiopathic arthritis (SJIA) (as monotherapy or in combination with methotrexate)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9773875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence as reported for monotherapy, except where noted. Combination therapy refers to use in rheumatoid arthritis with nonbiological DMARDs or use in SJIA in trials where most patients (~70%) were taking methotrexate at baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Hepatic: ALT increased (&le;36%; grades 3/4: &lt;1%), AST increased (&le;22%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (1% to 6%), peripheral edema (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (1% to 7%), dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (2%), skin reaction (combination therapy; 1% [includes pruritus, urticaria])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: LDL cholesterol increased (&gt;1.5-2 x ULN; combination therapy; children 2%), total cholesterol increased (&gt;1.5-2 x ULN; combination therapy; children 2%), hypothyroidism (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (children &le;5%), abdominal pain (2%), mouth ulceration (2%), gastric ulcer (&lt;2%), stomatitis (&lt;2%), weight gain (&lt;2%), gastritis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (combination therapy; grade 3: 2% to 7%; grade 4: &lt;1%), thrombocytopenia (combination therapy; 1% to 2%), leukopenia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Bilirubin increased (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Infusion-related reactions (combination therapy; 4% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Nephrolithiasis (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (7%), nasopharyngitis (7%), bronchitis (3%), cough (&lt;2%), dyspnea (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Anti-tocilizumab antibody formation (2%), herpes simplex (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic/anaphylactoid reaction, angioedema, aspergillosis, bacterial arthritis, candidiasis, cellulitis, chronic inflammatory demyelinating polyneuropathy, cryptococcus, diverticulitis, Epstein-Barr virus reactivation, gastroenteritis, gastrointestinal perforation, HDL cholesterol increased, herpes zoster, hypertriglyceridemia, malignancy (including breast and colon cancer), multiple sclerosis, otitis media, pneumonia, pneumonitis (allergic), pneumocystosis, sepsis, tuberculosis, urinary tract infection, varicella",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9773712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tocilizumab or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9773713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: May cause hypersensitivity, anaphylaxis, or anaphylactoid reactions (fatalities have been reported); hypersensitivity reactions have occurred in patients who were premedicated, in patients with and without a prior history of hypersensitivity, and as early as the first infusion. Stop infusion and permanently discontinue treatment in patients who develop a hypersensitivity reaction to tocilizumab. Medications for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated liver enzymes: Monitor transaminases. Treatment should be discontinued in patients who develop elevated ALT or AST &gt;5 x ULN. Patients receiving concomitant hepatotoxic drugs (eg, methotrexate) are at an increased risk of developing elevated transaminases; elevations are typically reversible and do not result in clinically evident hepatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fatal infections:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and potentially fatal infections (including active tuberculosis, invasive fungal, bacterial, viral, protozoal, and other opportunistic infections) have been reported in patients receiving tocilizumab. Most of the serious infections have occurred in patients on concomitant immunosuppressive therapy. Patients should be closely monitored for signs and symptoms of infection during and after treatment.  Prior to treatment initiation, carefully consider risk versus benefit in patients with chronic or recurrent infections,",
"     </b>",
"     tuberculosis exposure, history of or current opportunistic infection, underlying conditions predisposing to infection, or patients residing in or with travel to areas of endemic tuberculosis or endemic mycosis. The most common serious infections occurring have included pneumonia, UTI, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, and bacterial arthritis. Do not administer tocilizumab to a patient with an active infection, including localized infection. Interrupt treatment for serious infection, opportunistic infection or sepsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal perforation: Use with caution in patients at increased risk for gastrointestinal perforation; perforation has been reported, typically secondary to diverticulitis. Monitor for new-onset abdominal symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Herpes zoster reactivation: Herpes zoster reactivation has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Therapy is associated with increases in total cholesterol, triglycerides, LDL , and/or HDL; monitor ~4-8 weeks after initiation, then approximately every 6 months. Hyperlipidemia should be managed according to current guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy: Use of tocilizumab may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined, however, malignancies were observed in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis:",
"     <b>",
"      [U.S. Boxed Warning]: Tuberculosis (disseminated or extrapulmonary) has been reported in patients receiving tocilizumab; both reactivation of latent infection and new infections have been reported. Treatment of latent tuberculosis should be initiated before therapy is used.",
"     </b>",
"     Consider antituberculosis treatment in patients with a history of latent or active tuberculosis if adequate treatment course cannot be confirmed, and for patients with risk factors for tuberculosis despite a negative test. Patients should be evaluated for tuberculosis risk factors and tested for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Some patients who test negative prior to therapy may develop active infection; monitor for signs and symptoms of tuberculosis in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Demyelinating CNS disease: Use with caution in patients with pre-existing or recent onset CNS demyelinating disorders; rare cases of CNS demyelinating disorders (eg, multiple sclerosis) have occurred. All patients should be monitored for signs and symptoms of demyelinating disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use is not recommended in patients with active hepatic disease or hepatic impairment. Do not initiate treatment if ALT or AST is &gt;1.5 times ULN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia: Monitor neutrophil counts. Therapy should not be initiated in patients with an ANC &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; treatment should be discontinued in patients who develop an ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Monitor platelet counts. Therapy should not be initiated in patients with a platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; treatment should be discontinued in patients who develop a platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biological DMARDs: Concomitant use with other biological DMARDs (eg, TNF blockers, IL-1 receptor blockers, anti-CD20 monoclonal antibodies, selective costimulation modulators) should be avoided due to the increased risk of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution due to a higher incidence of serious infectious in elderly patients treated with tocilizumab.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of infection from live vaccines in patients receiving therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Product may contain polysorbate 80.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9774917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Tocilizumab may enhance the adverse/toxic effect of Abatacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: Tocilizumab may enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: Tocilizumab may decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Tocilizumab may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9773708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9773709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No evidence of impaired fertility, teratogenic, or dysmorphogenic effects in animal models; an increased incidence of abortion and embryo-fetal death has been observed in animal reproduction studies. Use during pregnancy only if clearly needed. A pregnancy registry has been established to monitor outcomes of women exposed to tocilizumab during pregnancy (877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9773710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9773711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tocilizumab is excreted in human milk. Because many immunoglobulins are excreted in human milk and the potential for serious adverse reactions exists, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Actemra Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/4 mL (4 mL): $344.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/10 mL (10 mL): $861.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/20 mL (20 mL): $1723.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9773961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of infection (prior to and during therapy); latent TB screening prior to therapy initiation; CBC with differential (prior to and every 2-4 weeks [SJIA] or 4-8 weeks [RA] during therapy); ALT/AST (prior to and every 2-4 weeks [SJIA] or 4-8 weeks [RA] during therapy); additional liver function tests (eg, bilirubin) as clinically indicated; lipid panel (prior to, at 4-8 weeks following initiation, and every ~6 months during therapy); signs and symptoms of CNS demyelinating disorders",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actemra (AR, AU, BR, CN, CO, EC, HK, ID, IL, IN, NZ, PE, PH, SG, TH);",
"     </li>",
"     <li>",
"      RoActemra (AT, BE, CH, CZ, DE, DK, EE, FR, GB, HN, IE, NL, NO, PL, PT, RU, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9773888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antagonist of the interleukin-6 (IL-6) receptor. Endogenous IL-6 is induced by inflammatory stimuli and mediates a variety of immunological responses. Inhibition of IL-6 receptors by tocilizumab leads to a reduction in cytokine and acute phase reactant production.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9773890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Children: 2.54 L; Adults: 6.4 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half life elimination: Terminal, single dose: 6.3 days (concentration-dependent; may be increased up to 23 days [children] or 13 days [adults] at steady state)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Emery P, Keystone E, Tony HP, et al, &ldquo;IL-6 Receptor Inhibition With Tocilizumab Improves Treatment Outcomes in Patients With Rheumatoid Arthritis Refractory to Anti-Tumour Necrosis Factor Biologicals: Results from a 24-Week Multicentre Randomised Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2008, 67(11):1516-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/18625622/pubmed\" id=\"18625622\" target=\"_blank\">",
"        18625622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Genovese MC, McKay JD, Nasonov EL, et al, &ldquo;Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs: The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(10):2968-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/18821691/pubmed\" id=\"18821691\" target=\"_blank\">",
"        18821691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maini RN, Taylor PC, Szechinski J, et al, &ldquo;Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who had an Incomplete Response to Methotrexate,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2006, 54(9):2817-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/16947782/pubmed\" id=\"16947782\" target=\"_blank\">",
"        16947782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nishimoto N, Hashimoto J, Miyasaka N, et al, &ldquo;Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, and IL-6 Inhibitor (SAMURAI): Evidence of Clinical and Radiographic Benefit from an X-Ray Reader-Blinded Randomised Controlled Trial of Tocilizumab,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2007, 66(9):1162-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/17485422/pubmed\" id=\"17485422\" target=\"_blank\">",
"        17485422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nishimoto N, Miyasaka N, Yamamoto K, et al, &ldquo;Long-Term Safety and Efficacy of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in Monotherapy, in Patients With Rheumatoid Arthritis (the STREAM study): Evidence of Safety and Efficacy in a 5-Year Extension Study,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2009, 68(10):1580-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/19019888/pubmed\" id=\"19019888\" target=\"_blank\">",
"        19019888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nishimoto N, Miyasaka N, Yamamoto K, et al, &ldquo;Study of Active Controlled Tocilizumab Monotherapy for Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (SATORI): Significant Reduction in Disease Activity and Serum Vascular Endothelial Growth Factor by IL-6 Receptor Inhibition Therapy,&rdquo;",
"      <i>",
"       Mod Rheum",
"      </i>",
"      , 2009, 19(1):12-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/18979150 /pubmed\" id=\"18979150 \" target=\"_blank\">",
"        18979150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oldfield V, Dhillon S, and Plosker GL, &ldquo;Tocilizumab: A Review of its Use in the Management of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2009, 69(5):609-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/19368420/pubmed\" id=\"19368420\" target=\"_blank\">",
"        19368420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plushner SL, &ldquo;Tocilizumab: An Interleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 429(11):1660-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/18957621/pubmed\" id=\"18957621\" target=\"_blank\">",
"        18957621",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolen JS, Beaulieu A, Rubbert-Roth A, et al, &ldquo;Effect of Interleukin-6 Receptor Inhibition With Tocilizumab in Patients With Rheumatoid Arthritis (OPTION study): A Double-Blind, Placebo-Controlled, Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9617):987-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/19/44342/abstract-text/18358926/pubmed\" id=\"18358926\" target=\"_blank\">",
"        18358926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10208 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44342=[""].join("\n");
var outline_f43_19_44342=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773700\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9756027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10819878\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773705\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773954\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12780726\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773955\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773956\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773957\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773963\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773703\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773701\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773959\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773707\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773875\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773713\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300151\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9774917\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773709\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773710\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773711\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322788\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773961\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962019\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773888\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773890\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10208|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/63/1013?source=related_link\">",
"      Tocilizumab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/14/9446?source=related_link\">",
"      Tocilizumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_19_44343="Cervical intraepithelial neoplasia: Ablative therapies";
var content_f43_19_44343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical intraepithelial neoplasia: Ablative therapies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44343/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44343/contributors\">",
"     Nicholas P Taylor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44343/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44343/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44343/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44343/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/19/44343/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical intraepithelial neoplasia (CIN) is a premalignant cervical disease that is also called cervical dysplasia or cervical squamous intraepithelial lesions (CSIL). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link&amp;anchor=H1#H1\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of CIN can either be excisional (ie, conization) or ablative. Ablative modalities are solely for treatment, while excisional therapy provides diagnostic information as well as therapeutic benefit.",
"   </p>",
"   <p>",
"    Ablative therapies of the cervix will be discussed in this topic review. In addition, choosing between excision and ablation, as well as between ablative methods will be reviewed. Excisional methods for CIN treatment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;American Society for Colposcopy and Cervical Pathology guidelines include ablative therapy as a reasonable option for managing women with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent CIN1 for two or more years",
"     </li>",
"     <li>",
"      CIN 2 or CIN 3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients must meet specific eligibility criteria, described below.",
"   </p>",
"   <p>",
"    The management of CIN is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR ABLATIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for ablative therapy should have no suspicion of invasive disease and no endocervical disease. To satisfy these criteria, the patient must have had all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Satisfactory colposcopy (visualization of entire cervical squamocolumnar junction).",
"     </li>",
"     <li>",
"      Biopsy confirming presence of CIN; abnormal cytology alone is not sufficient.",
"     </li>",
"     <li>",
"      Negative endocervical curettage",
"     </li>",
"     <li>",
"      Cytology and histology that correspond with each other (eg, CIN1 histology preceded by cytologies which are likely associated with a low grade lesion: atypical squamous cell of unknown significance, atypical squamous cell cannot exclude high grade squamous intraepithelial lesion, or low grade squamous intraepithelial lesion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although, there are no data regarding these populations, ablative therapy should be avoided in pregnant women due to potential risk of obstetric complications, and in those who have a history of a previous ablative or excisional cervical procedure or who are not compliant with follow-up, due to concern about a missed diagnosis of cervical cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=see_link\">",
"     \"Cervical cancer in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An excisional procedure should be performed in patients who are not appropriate candidates for ablation. Excisional biopsy is recommended for women with cytological findings potentially associated with high-grade lesions (ie, high-grade squamous intraepithelial lesion, atypical glandular cells).",
"   </p>",
"   <p>",
"    Patient-specific risk of complications (eg, bleeding diathesis), patient and physician preference, and cost also play a role in the choice of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL PROCEDURAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy and cold coagulation are office procedures. Both CO2 laser ablation and electrocoagulation diathermy may be performed in an office setting, but as they are more painful to patients, general anesthesia in an operating room may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Routine preoperative laboratory tests, cultures, and antibiotic prophylaxis are not required.",
"   </p>",
"   <p>",
"    We pre-treat with an oral non-steroidal inflammatory drug (NSAID) to minimize procedure related cramping (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    600 mg). A local anesthetic should be provided. Options include injection into the cervical stroma or as a paracervical block; we prefer a stromal block. In one decision analysis, stromal block was the most cost-effective method to avert the pain and cramping during cryosurgery (in women who have taken a NSAID before the procedure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=see_link&amp;anchor=H17#H17\">",
"     \"Pudendal and paracervical block\", section on 'Paracervical block (Gynecologic)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For all techniques, the cervix is stained with Lugol's iodine (a solution of elemental iodine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    in water) to delineate the lesion to be ablated.",
"   </p>",
"   <p>",
"    Most patients will report minor cramping, similar to menstrual cramps, during and after the procedure. Vasomotor symptoms (eg, light-headedness) may occur, and are more common during cryotherapy than during laser ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ABLATIVE TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy and laser ablation are the most commonly used methods for cervical ablation. Cold coagulation and diathermy are rarely used in the United States.",
"   </p>",
"   <p>",
"    CIN can extend into glandular crypts, thus, the depth of cervical ablation should be at least 4.8 mm for all techniques. This will adequately treat greater than 99 percent of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy uses a refrigerant gas (carbon dioxide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    ) to cool the ectocervix with a metal cryoprobe. The ectocervix must be cooled to -20&ordm;C to cause crystallization of intracellular water and destroy the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/8\">",
"     8",
"    </a>",
"    ]. This can be achieved by forming an ice ball in the cervical tissue that is at least 5 mm from the tip of the probe.",
"   </p>",
"   <p>",
"    Cryoprobes are either flat or cone-shaped and vary in diameter (19 or 25 mm). It is not clear whether cryoprobe shape influences treatment efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Selection of the appropriate cryoprobe is controversial. In one study (n = 64), cryotherapy was performed on women prior to hysterectomy, and postoperative histology revealed that adequate tissue destruction (in this study, defined as 4 mm depth and &le;15 mm width) was significantly more likely after use of the large cone-shaped probe (25 mm diameter) than the small flat probe (19 mm diameter) (80 versus 58 percent); results for the other probes (small cone-shaped and large flat) did not differ significantly from the others (67 and 72 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in a randomized trial (n = 117) women with CIN were assigned to cryotherapy with either a cone-shaped or flat probe (selection of large or small probe was made according to size of cervix), rates of disease found at follow-up colposcopy were similar (77 and 76 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of refrigerant gas may also influence outcome. Tissue crystallization induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    appears to penetrate deeper into the cervical stroma than CO2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      - Select the appropriate probe and apply a water soluble lubricant to the probe tip to allow adequate transfer of thermal energy between the probe and the cervical tissue. A note of caution, if the cryoprobe makes contact with the speculum, vaginal tissue in contact with the speculum will also be ablated. An insulated speculum may be used, but is not required.",
"      <br/>",
"      <br/>",
"      Activate the cryotherapy unit and, when the optimal freezing temperature is achieved (-65&ordm;C to -85&ordm;C), administer a three-minute freeze and then turn the unit off to allow the cervix to thaw. The probe will then fall free of the cervix and a white \"frost\" area will be visible. Removing the probe, rather than allowing it to fall off, will cause pain and bleeding. Continue to allow the cervix to defrost and become pink.",
"      <br/>",
"      <br/>",
"      Perform a second freeze and again allow the cervix to defrost [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/12\">",
"       12",
"      </a>",
"      ]. In a large meta-analysis of randomized trials, using two",
"      <span class=\"nowrap\">",
"       freeze/thaw",
"      </span>",
"      cycles was more effective than one cycle (residual disease rates at 27-month follow-up were 6 versus 16 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CO2 laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser surgery should only be performed by physicians with specialized training. The laser is directed at the cervical lesion under colposcopic guidance. Water in the tissue absorbs the laser energy, which destroys the tissue by vaporization. To be effective, the lesion is typically ablated to a depth of 5 mm on the ectocervix and 8 to 9 mm around the endocervix.",
"   </p>",
"   <p>",
"    Laser ablation of visible lesions is discussed here, a full discussion of laser conization (ie, the transformation zone is excised using a laser) and principles of laser therapy can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=see_link&amp;anchor=H4#H4\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\", section on 'Laser conization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      - Protective eye wear is necessary for any personnel in the procedure room. To avoid inadvertent damage to the surrounding areas from a reflected or misdirected laser beam, use a blackened or brushed speculum and drape the patient's perineum and thighs with wet towels. Avoid paper drapes, as they are flammable.",
"      <br/>",
"      <br/>",
"      Visualize the cervix using a colposcope. Using a CO2 laser with a power density of 600 to 1200",
"      <span class=\"nowrap\">",
"       watts/cm2",
"      </span>",
"      is adequate for vaporization. For example, with a spot size of 2 mm, setting the laser to 35 watts will produce a power density of 875",
"      <span class=\"nowrap\">",
"       watts/cm2.",
"      </span>",
"      In generally, obtaining hemostasis requires a spot size of 5 mm or greater.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Technique varies among surgeons, and there are no data comparing these methods. Some experts advocate using the laser in ultrapulse mode to decrease thermal damage to the surrounding cervical stroma. Also, some experts advise lasering the ectocervix with a defocused beam to provide a several millimeter margin around the area previously ablated (ie, \"brush\" lasering).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cold coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the term \"cold\" coagulation, this method uses heat to ablate the cervical stroma. The term \"cold\" coagulation is used because lower temperatures are used compared with electrocoagulation diathermy ablation (see below). Similar to cryotherapy, a probe (thermosound) is used to conduct heat to the cervix. Probe temperatures vary from 50&ordm;C to 120&ordm;C. Depth of penetration into the cervical stroma depends on the temperature of the probe and duration of probe application.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      - Cold coagulation is not commonly used, and a standard technique has not been established. In the largest single-institution experience, a temperature of 100&ordm;C was applied for 20 seconds with overlapping treatment fields for a total treatment time of 40 to 100 seconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diathermy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term diathermy means \"electrically induced heat\". This technique uses a needle that is attached to an electrosurgical generator (cautery device) to destroy cervical tissue.",
"   </p>",
"   <p>",
"    Diathermy is primarily performed as an inpatient procedure requiring general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], but it can be used in the outpatient setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      - The diathermy needle is passed into and out of the cervix multiple times to ablate the transformation zone; a spatula can be used to remove desiccated tissue. A setting of 30 to 35 watts has been described, but there does not appear to be a consensus on the optimal current [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/14\">",
"       14",
"      </a>",
"      ]. The speculum should not touch the diathermy needle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, all types of ablative therapy for CIN appear to be effective, with low rates of disease persistence and recurrence (generally &lt;10 percent) at seven or more years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/15,17-24\">",
"     15,17-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the high success rates with ablative modalities (particularly CO2 laser and cryotherapy), CIN2 or 3 or cancer can be missed without an excisional biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, complication rates after ablative therapy are low, approximately 1 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, women are more likely to experience discharge after cryotherapy than laser ablation, while the risk of bleeding is higher after laser ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cryotherapy patients, watery vaginal discharge generally continues for several weeks after treatment. When patients find the discharge bothersome, we remove the necrotic tissue from the cervix using ring forceps.",
"   </p>",
"   <p>",
"    Patients with post-treatment bleeding are evaluated with a speculum exam. Bleeding is usually minimal and will resolve with conservative measures in the office, such as application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/18/19747?source=see_link\">",
"     ferric subsulfate",
"    </a>",
"    (Monsel's solution). It is rare to encounter bleeding which requires suturing or packing.",
"   </p>",
"   <p>",
"    Pelvic infection after ablation is infrequent, but may be increased in patients with other risk factors for pelvic inflammatory disease (PID). For example, in one series of 67 adolescents treated with cryotherapy, nine percent developed PID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Late complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible late complications are cervical stenosis or obstetric complications.",
"   </p>",
"   <p>",
"    Cervical stenosis appears to be rare after with cryotherapy or laser ablation, however, there are few data regarding this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In the largest series of cryotherapy or laser ablation, the risk of stenosis was one percent or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Although a randomized trial found no significant difference in the incidence of cervical stenosis between the two methods, there was insufficient statistical power to detect a difference in this rare complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=see_link&amp;anchor=H23#H23\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Cervical stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence that the risk of cervical stenosis following cervical ablation is increased for women with a history of in-utero exposure to diethylstilbestrol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=see_link\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of obstetric complications (eg, preterm delivery) appears to be lower in women treated with ablative rather than excisional methods. A full discussion of the association of treatment of CIN with obstetric complications can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;We see patients at 10 to 14 days after the procedure and treat any short-term complications. Appropriate follow-up after ablative treatment for CIN is especially critical, as no pathologic diagnosis is obtained at the time of treatment and some patients will go on to develop cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After laser ablation, the squamocolumnar junction usually returns to its pre-treatment location and can be visualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"     6",
"    </a>",
"    ]. However, following cryotherapy, the squamocolumnar junction may recede into the cervical canal, making subsequent colposcopy difficult. Radial scar lines may also be seen with subsequent colposcopies, and are of no clinical significance.",
"   </p>",
"   <p>",
"    Recommendations for follow-up after treatment for CIN are discussed in detail separately elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CHOOSING A TREATMENT METHOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal difference between ablative and excisional methods is that ablation provides no diagnostic information. As noted above, patients in whom there is diagnostic uncertainty or who are not likely to comply with follow-up should not be treated with ablative therapy.",
"   </p>",
"   <p>",
"    For women who are candidates for either type of treatment, the choice of ablative or excisional therapy depends primarily upon effectiveness. Additional factors that influence the decision are risk of adverse effects, cost, convenience, and, possibly, future reproductive plans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, both ablation and excision are effective, and there is no evidence that either approach is superior. Some, but not all methods of ablation and excision have been compared directly to one another. A meta-analysis of randomized trials evaluated outcomes in women with any degree of CIN. Effective treatment is defined as the absence of persistent or recurrent disease. Major findings are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laser ablation compared with excision by loop electrosurgical excision procedure (LEEP) showed no significant difference in effectiveness (OR 1.0, 95% CI 0.6-1.6) or laser conization (OR 0.7, 95% CI, 0.2-2.9) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laser ablation compared with cryotherapy showed no significant difference in effectiveness (OR 0.96, 95% CI 0.67-1.36).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no high quality data comparing cryotherapy or laser ablation with cold knife conization. Observational studies suggest that, for women with any degree of CIN, laser ablation is more effective than cold knife conization; effectiveness of cryotherapy does not differ significantly from cold knife conization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Additional considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Low versus high grade disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a few studies, effectiveness was evaluated separately for women with low- versus high-grade disease. We take grade-specific evidence into account when planning a treatment approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CIN1",
"      </strong>",
"      - For women treated for persistent CIN1, we prefer ablation to conization because excision is associated with a risk of subsequent preterm delivery. However, in settings where ablation equipment is not available, LEEP is a reasonable choice. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Women planning pregnancy'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      We prefer cryotherapy to laser ablation. There is some evidence that cryotherapy is more effective than laser ablation for women with CIN1. A subgroup analysis of the meta-analysis discussed above found women with CIN1 who were treated with laser ablation had a higher risk of residual disease than those who were treated with cryotherapy (OR 3.3, 95% CI 1.1-10.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The strength of this conclusion is attenuated by the use of an unplanned subgroup analysis and by the methodological flaws in the included trials; however, cryotherapy has several other advantages over laser ablation in this population. Cryotherapy is associated with less perioperative pain and bleeding than laser ablation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"       6",
"      </a>",
"      ]. Also, laser equipment is costly, and a laser procedure may require general anesthesia in an inpatient setting, whereas cryotherapy is a relatively simple office procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/2,4,32\">",
"       2,4,32",
"      </a>",
"      ]. A disadvantage of cryotherapy is that a malodorous vaginal discharge is a common side effect and vasomotor symptoms may occur during the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"       6",
"      </a>",
"      ]; however, these effects are easily managed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cryotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       CIN 2,3",
"      </strong>",
"      - In our practice, we treat women with CIN 2,3 with conization (LEEP, cold knife, or laser) rather than ablation due to concerns about effectiveness and morbidity. &nbsp;",
"      <br/>",
"      <br/>",
"      We recommend against using cryotherapy in patients with high-grade CIN because it is less effective than excision in this patient population. In the only randomized trial (n=400) to address this question, women with high-grade disease who underwent cryotherapy had a significantly greater risk of persistent or recurrent disease than those who underwent LEEP (12 versus 4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/33\">",
"       33",
"      </a>",
"      ]. &nbsp;",
"      <br/>",
"      <br/>",
"      Also, it remains unclear whether laser ablation is as effective as conization. In women with high-grade disease, the risk of forgoing diagnostic information and missing a cervical cancer requires that use of any therapy other than excision be supported by high quality evidence. While a meta-analysis of randomized trials reported that LEEP and laser ablation have no significant difference in effectiveness (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment effectiveness'",
"      </a>",
"      above), the included trials had methodologic flaws and the conclusions were inconsistent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"       6",
"      </a>",
"      ]. &nbsp;",
"      <br/>",
"      <br/>",
"      Inconsistencies across comparisons of methods add to the clinical uncertainty. In the meta-analysis mentioned above, laser ablation showed no difference in effectiveness compared with either LEEP or cryotherapy. However, a well designed randomized trial found cryotherapy to be inferior to LEEP in women with high-grade disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/33\">",
"       33",
"      </a>",
"      ]. &nbsp; Comparisons of morbidity between LEEP and laser ablation depend upon patient preference. While excisional methods are typically associated with greater morbidity, laser ablation is associated with significantly more perioperative pain than LEEP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"       6",
"      </a>",
"      ]. &nbsp;",
"      <br/>",
"      <br/>",
"      However, women planning a subsequent pregnancy may prefer to take some risk of disease recurrence to offset the risk of preterm delivery. These women should be offered the choice of either laser ablation or excision and counseled about the risks and benefits of each. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Women planning pregnancy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Large lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality data regarding the efficacy of ablation versus excision in women with large versus small lesions. We prefer excisional therapy to laser ablation for women with CIN3, particularly for lesions that involve more than three quadrants colposcopically or are greater than 3 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44343/abstract/20,34\">",
"     20,34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Candidates for ablative therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Women planning pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effectiveness of treatment is the priority for most patients, however, when effectiveness of two methods is comparable, we prefer ablation to excision because excision appears to increase the risk of preterm delivery in subsequent pregnancies.",
"   </p>",
"   <p>",
"    Thus, ablation is preferred to excision for women treated for persistent CIN1; however, LEEP may be used where ablation is not available. For women with small CIN2 or 3 lesions, laser ablation is a reasonable option. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=see_link\">",
"       \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=see_link\">",
"       \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/57/14227?source=see_link\">",
"       \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ablative therapy is an effective treatment for women with high-grade and persistent low grade cervical intraepithelial neoplasia (CIN) in whom there is no suspicion of glandular or invasive squamous disease and who are compliant with follow-up. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidates for ablative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most commonly used techniques for cervical ablation are cryotherapy and laser ablation; cold coagulation and electrocoagulation diathermy are used infrequently. Most procedures can be performed in an office setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ablative techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incidence of adverse effect and complications after ablative therapy are low, approximately 1 to 2 percent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adverse effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ablative modalities are solely for treatment, while excisional therapy provides diagnostic information as well as therapeutic benefit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Choosing a treatment method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing cryotherapy, we recommend two",
"      <span class=\"nowrap\">",
"       freeze/thaw",
"      </span>",
"      cycles rather than one cycle (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Choosing a treatment method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with CIN1, we suggest ablative over excisional therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Loop electrosurgical excision procedure is an acceptable alternative, in clinics that do not have ablation equipment. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Additional considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with CIN1 who are undergoing ablative therapy, we suggest cryotherapy rather than laser ablation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Choosing a treatment method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with CIN2 or 3, we recommend against treatment with cryotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Choosing a treatment method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women with CIN2 or 3, we suggest excision over laser ablation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Women with CIN2 or small CIN3 lesions who anticipate a subsequent pregnancy may reasonably choose laser ablation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Choosing a treatment method'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/1\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/2\">",
"      Wetchler SJ. Treatment of cervical intraepithelial neoplasia with the CO2 laser: laser versus cryotherapy. A review of effectiveness and cost. Obstet Gynecol Surv 1984; 39:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/3\">",
"      Schuurmans SN, Ohlke ID, Carmichael JA. Treatment of cervical intraepithelial neoplasia with electrocautery: report of 426 cases. Am J Obstet Gynecol 1984; 148:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/4\">",
"      Johnson N, Crompton AC. Who finds cervical laser therapy painful? Gynecol Oncol 1994; 52:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/5\">",
"      Harper DM, Cobb JL. Is it cost-effective to use a mucosal or paracervical block to relieve the pain and cramping from cryosurgery? A decision model. J Fam Pract 1999; 48:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/6\">",
"      Martin-Hirsch PL, Paraskevaidis E, Kitchener H. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2000; :CD001318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/7\">",
"      Abdul-Karim FW, Fu YS, Reagan JW, Wentz WB. Morphometric study of intraepithelial neoplasia of the uterine cervix. Obstet Gynecol 1982; 60:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/8\">",
"      Hatch KD. Cryotherapy. Baillieres Clin Obstet Gynaecol 1995; 9:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/9\">",
"      Boonstra H, Koudstaal J, Oosterhuis JW, et al. Analysis of cryolesions in the uterine cervix: application techniques, extension, and failures. Obstet Gynecol 1990; 75:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/10\">",
"      Stienstra KA, Brewer BE, Franklin LA. A comparison of flat and shallow conical tips for cervical cryotherapy. J Am Board Fam Pract 1999; 12:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/11\">",
"      Mariategui J, Santos C, Taxa L, et al. Comparison of depth of necrosis achieved by CO2- and N2O-cryotherapy. Int J Gynaecol Obstet 2008; 100:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/12\">",
"      Creasman WT, Weed JC Jr, Curry SL, et al. Efficacy of cryosurgical treatment of severe cervical intraepithelial neoplasia. Obstet Gynecol 1973; 41:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/13\">",
"      Duncan ID. Cold coagulation. Baillieres Clin Obstet Gynaecol 1995; 9:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/14\">",
"      Woodman CB, Jordan JA, Mylotte MJ, et al. The management of cervical intraepithelial neoplasia by coagulation electrodiathermy. Br J Obstet Gynaecol 1985; 92:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/15\">",
"      Chanen W, Rome RM. Electrocoagulation diathermy for cervical dysplasia and carcinoma in situ: a 15-year survey. Obstet Gynecol 1983; 61:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/16\">",
"      Giles JA, Walker PG, Chalk PA. Treatment of cervical intraepithelial neoplasia (CIN) by radical electrocoagulation diathermy: 5 years' experience. Br J Obstet Gynaecol 1987; 94:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/17\">",
"      Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998; 92:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/18\">",
"      Kwikkel HJ, Helmerhorst TJ, Bezemer PD, et al. Laser or cryotherapy for cervical intraepithelial neoplasia: a randomized study to compare efficacy and side effects. Gynecol Oncol 1985; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/19\">",
"      Townsend DE, Richart RM. Cryotherapy and carbon dioxide laser management of cervical intraepithelial neoplasia: a controlled comparison. Obstet Gynecol 1983; 61:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/20\">",
"      Ferenczy A. Comparison of cryo- and carbon dioxide laser therapy for cervical intraepithelial neoplasia. Obstet Gynecol 1985; 66:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/21\">",
"      Chew GK, Jandial L, Paraskevaidis E, Kitchener HC. Pattern of CIN recurrence following laser ablation treatment: long-term follow-up. Int J Gynecol Cancer 1999; 9:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/22\">",
"      Draeby-Kristiansen J, Garsaae M, Bruun M, Hansen K. Ten years after cryosurgical treatment of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1991; 165:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/23\">",
"      Gordon HK, Duncan ID. Effective destruction of cervical intraepithelial neoplasia (CIN) 3 at 100 degrees C using the Semm cold coagulator: 14 years experience. Br J Obstet Gynaecol 1991; 98:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/24\">",
"      Cirisano FD. Management of pre-invasive disease of the cervix. Semin Surg Oncol 1999; 16:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/25\">",
"      Hillard PA, Biro FM, Wildey L. Complications of cervical cryotherapy in adolescents. J Reprod Med 1991; 36:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/26\">",
"      Loobuyck HA, Duncan ID. Destruction of CIN 1 and 2 with the Semm cold coagulator: 13 years' experience with a see-and-treat policy. Br J Obstet Gynaecol 1993; 100:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/27\">",
"      Baggish MS, Dorsey JH, Adelson M. A ten-year experience treating cervical intraepithelial neoplasia with the CO2 laser. Am J Obstet Gynecol 1989; 161:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/28\">",
"      Schmidt G, Fowler WC Jr. Cervical stenosis following minor gynecologic procedures on DES-exposed women. Obstet Gynecol 1980; 56:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/29\">",
"      Kalstone C. Cervical stenosis in pregnancy: a complication of cryotherapy in diethylstilbestrol-exposed women. Am J Obstet Gynecol 1992; 166:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/30\">",
"      Shumsky AG, Stuart GC, Nation J. Carcinoma of the cervix following conservative management of cervical intraepithelial neoplasia. Gynecol Oncol 1994; 53:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/31\">",
"      Kalliala I, Nieminen P, Dyba T, et al. Cancer free survival after CIN treatment: comparisons of treatment methods and histology. Gynecol Oncol 2007; 105:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/32\">",
"      Kleinberg MJ, Straughn JM Jr, Stringer JS, Partridge EE. A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3. Am J Obstet Gynecol 2003; 188:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/33\">",
"      Chirenje ZM, Rusakaniko S, Akino V, Mlingo M. A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia. J Obstet Gynaecol 2001; 21:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44343/abstract/34\">",
"      Creasman WT, Hinshaw WM, Clarke-Pearson DL. Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet Gynecol 1984; 63:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3212 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-201.65.114.212-EEAAC3DE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44343=[""].join("\n");
var outline_f43_19_44343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANDIDATES FOR ABLATIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL PROCEDURAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ABLATIVE TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CO2 laser",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cold coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diathermy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADVERSE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Late complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CHOOSING A TREATMENT METHOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Additional considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Low versus high grade disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Large lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Women planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=related_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=related_link\">",
"      Cervical intraepithelial neoplasia: Reproductive effects of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=related_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_19_44344="Evaluation of hearing impairment in children";
var content_f43_19_44344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of hearing impairment in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44344/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44344/contributors\">",
"     Richard JH Smith, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44344/contributors\">",
"     Adrian Gooi, MD, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44344/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44344/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/19/44344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss in children can be a silent handicap. Children with hearing loss frequently appear to be normal. Hearing loss that is undetected and untreated can result in speech, language, and cognitive delays. Early identification and effective treatment of hearing loss improve language, communication, and cognitive skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of hearing impairment in children is reviewed here. The etiology and treatment of hearing loss in children are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"mobipreview.htm?4/62/5101\">",
"     table 1",
"    </a>",
"    ). Newborn hearing screening is also covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=see_link\">",
"     \"Screening the newborn for hearing loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with hearing loss should have a complete history, physical examination, and formal audiologic testing to determine the type and etiology of hearing loss and the optimal treatment plan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Infants with hearing loss should be evaluated by an otolaryngologist who is knowledgeable in pediatric hearing loss and should have at least one examination to assess visual acuity by an ophthalmologist who is experienced in evaluating infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/7\">",
"     7",
"    </a>",
"    ]. In a series of 226 children with sensorineural hearing loss, the prevalence of ophthalmologic abnormalities was 22 percent (compared with approximately 14 percent in the general population) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Refractive errors (myopia, hyperopia, astigmatism) were more frequent than nonrefractive conditions (eg, strabismus, amblyopia, nystagmus, optic atrophy, retinitis pigmentosa).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important questions in the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What was the onset and progression of the hearing loss?",
"     </li>",
"     <li>",
"      Is there pain or drainage from the ear associated with the hearing loss?",
"     </li>",
"     <li>",
"      Is there associated tinnitus, vertigo, or disequilibrium?",
"     </li>",
"     <li>",
"      Is there associated night blindness, decreased visual acuity, or visual field defect?",
"     </li>",
"     <li>",
"      Is the child a late walker or very off balance?",
"     </li>",
"     <li>",
"      Is there associated kidney disease or cardiac dysrhythmia?",
"     </li>",
"     <li>",
"      Is there a history of congenital infection, recurrent otitis media, or meningitis?",
"     </li>",
"     <li>",
"      Is there a history of exposure to ototoxic drugs or substances?",
"     </li>",
"     <li>",
"      Is there a history of significant trauma, including noise and barotrauma?",
"     </li>",
"     <li>",
"      Is there a history of previous ear surgery?",
"     </li>",
"     <li>",
"      Is there a history of prematurity or birth complications?",
"     </li>",
"     <li>",
"      Is there a history of hyperbilirubinemia?",
"     </li>",
"     <li>",
"      Is there a family history of hearing loss?",
"     </li>",
"     <li>",
"      Is there a family history of retinitis pigmentosa?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should include measurement of growth parameters and assessment of general appearance, while looking for the clinical features of various syndromes (",
"    <a class=\"graphic graphic_table graphicRef66758 \" href=\"mobipreview.htm?12/21/12638\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/11\">",
"     11",
"    </a>",
"    ]. As examples, a white forelock and heterochromia of the iris are seen in Waardenburg syndrome, micrognathia in Apert syndrome and Robin sequence, and enlarged thyroid in Pendred syndrome. Examination of the head and neck is especially important. In a retrospective analysis of 114 children with hearing loss referred to a tertiary care center, 43 percent had head and neck abnormalities that helped to establish the etiology of hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H24#H24\">",
"     \"The genodermatoses\", section on 'Waardenburg syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/18/8487?source=see_link&amp;anchor=H2#H2\">",
"     \"Craniosynostosis syndromes\", section on 'Apert syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/250?source=see_link&amp;anchor=H9#H9\">",
"     \"Syndromes with craniofacial abnormalities\", section on 'Robin sequence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24280?source=see_link&amp;anchor=H4#H4\">",
"     \"Congenital and acquired goiter in children\", section on 'Inborn errors of thyroid hormone production'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ear examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the outer ear includes inspection for preauricular pits or sinuses, pinna size and shape, and patency of the external auditory canal. The external auditory canal should be cleared of cerumen for more accurate hearing testing. The tympanic membrane should be viewed to ensure that no middle ear abnormality (eg, middle ear fluid, tympanic membrane perforation, tympanic membrane scarring, cholesteatoma or other middle ear mass) exists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12055?source=see_link\">",
"     \"Congenital anomalies of the ear\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=see_link&amp;anchor=H26#H26\">",
"     \"The pediatric physical examination: HEENT\", section on 'Ears'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumatic otoscopy is performed with positive and negative pressure to evaluate mobility of the tympanic membrane. Diminished or absent tympanic membrane mobility can be caused by fluid, mass in the middle ear cavity, perforation, pressure equalization tube, or sclerosis of the tympanic membrane. Increased mobility of the tympanic membrane can indicate ossicular chain disruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Office hearing tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older children and adolescents, hearing status can be assessed in the office using 256 Hz and 512 Hz tuning forks; hearing loss at 256 Hz is equivalent to approximately 10 to 15 decibels (dB), and hearing loss at 512 Hz is equivalent to 20 to 30 dB. An ear with normal hearing has air conduction (sound waves traveling to the tympanic membrane and converted into sound in the inner ear) that is louder than bone conduction (sound transmitted via the vibration of the skull into the cochlea). The Weber and Rinne tests examine the relative adequacy of air and bone conduction of sound (",
"    <a class=\"graphic graphic_figure graphicRef58032 \" href=\"mobipreview.htm?40/5/41043\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74488 \" href=\"mobipreview.htm?31/32/32268\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Weber test is performed by placing the tuning fork on the bridge of the forehead, nose, or teeth and asking the child if the sound is louder in one ear or the other. The sound is heard equally in both ears in children with normal hearing. Sensorineural hearing loss is suspected if the vibratory sound is louder on the \"good\" side; conductive hearing loss is suspected if the vibratory sound is louder on the \"bad\" side.",
"     </li>",
"     <li>",
"      The Rinne test compares bone conduction (when the tuning fork is placed on the mastoid bone) to air conduction (when the tuning fork is held near the ear). The test is negative when bone conduction is greater than air conduction; a negative test is consistent with conductive hearing loss, especially if the Weber test also lateralizes to that side. The Rinne test is positive (or normal) when air conduction is greater than bone conduction. Sensorineural hearing loss is suspected when the Weber test lateralizes to an ear in which the Rinne test was positive and the Rinne test in the opposite ear is also positive.",
"     </li>",
"     <li>",
"      As examples, a conductive hearing loss on the right side would demonstrate a Weber test that lateralizes to the right (ipsilateral side), a Rinne test which is negative (bone conduction greater than air conduction) on the right, and a Rinne test which is normal (positive) on the left. A sensorineural hearing loss on the right side would demonstrate a Weber test that lateralizes to the left (contralateral side), and normal (positive) Rinne tests bilaterally. Testing results may vary for mixed hearing loss, severe sensorineural hearing loss (Rinne test on the bad ear will appear to be negative, because bone conduction crosses over and is detected by the good ear), or conductive hearing loss below the thresholds that are detectable by the tuning forks used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OFFICE AUDIOLOGY SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Objective audiologic screening is recommended for all newborns and periodically for children between 4 and 11 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/13\">",
"     13",
"    </a>",
"    ]. Pure tone audiometry, tympanometry, or otoacoustic emission testing (OAE) may be performed by the primary care provider. Pure tone audiometry and OAE may be performed in a quiet room rather than an expensive soundproof environment, but may fail to detect mild hearing losses (&lt;30 dB). Any patient with abnormal office audiometry should be referred for formal audiology testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/14\">",
"     14",
"    </a>",
"    ]. The schedule and indications for hearing screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43225?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening tests in children and adolescents\", section on 'Hearing screen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pure tone audiometry in the office involves determining the softest decibel threshold at which the child can hear a sound 50 percent of the time for each tested frequency. This is plotted on a graph showing hearing threshold (dB) as a function of frequency (Hz), with louder thresholds marked lower on the graph. Normal hearing threshold is between 0 to 20 dB. Often only air thresholds are tested in the office setting. Accurate results are dependent upon cooperation from the child. Any threshold &gt;20 dB suggests a hearing loss (conductive, sensorineural, or mixed). Conductive hearing loss is suggested in the setting of fluid in the middle ear or a flat tympanogram.",
"   </p>",
"   <p>",
"    Otoacoustic emission (OAE) testing is another pediatric hearing screening test. This test measures the presence and strength of low-intensity sound (OAE) produced by the cochlea in response to an acoustic stimulus. Testing does not require a behavioral response from the child; however, a quiet setting is still needed. An abnormal OAE may be due to cochlear dysfunction or conductive hearing loss.",
"   </p>",
"   <p>",
"    Tympanometry can be used as a screening tool for otitis media with effusion (OME) that is often associated with conductive hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/15\">",
"     15",
"    </a>",
"    ]. Tympanometry is most valuable in conjunction with pneumatic otoscopy. Flat tympanograms (type B tympanograms) (",
"    <a class=\"graphic graphic_figure graphicRef67750 \" href=\"mobipreview.htm?2/34/2595\">",
"     figure 2",
"    </a>",
"    ) are usually due to middle ear effusion (acute otitis media or otitis media with effusion [also known as serous otitis media or middle ear effusion]). A hearing evaluation and referral to an otolaryngologist may be warranted if the abnormalities fail to resolve with appropriate therapy (for acute otitis media) or during the expected time frame (for otitis media with effusion). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FORMAL AUDIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal audiologic assessment is performed by an audiologist in a soundproof environment and provides detailed information about hearing ability. Every audiologic workup consists of numerous studies. The age of the child, the reason for the referral, the test environment, the equipment available, and the skill of the test administrator determine which tests will be performed. No child is too young to have his or her hearing evaluated. Children who have abnormal formal audiology results should be referred to otolaryngology, speech-language pathology, genetics, and early intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pure tone audiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Audiology measures the ability to hear pure tones of various frequencies as a function of intensity measured in decibels. The pure tone frequencies evaluated in a complete audiogram are 250 Hz, 500 Hz, 1000 Hz, 2000 Hz, 3000 Hz, 4000 Hz, and 8000 Hz. The threshold for each tone is determined by finding the intensity level at which the child can detect the tone 50 percent of the time.",
"   </p>",
"   <p>",
"    Hearing is tested with both air and bone conduction. Air conduction, performed with earphones, tests the ability to hear when sound waves travel their normal route through the external auditory canal to the tympanic membrane and the middle ear system. Bone conduction, performed with an oscillator placed on the mastoid bone, tests the ability to hear when the middle ear is bypassed and the inner ear fluid and cochlea are stimulated directly with bone vibration.",
"   </p>",
"   <p>",
"    Hearing loss is defined by the pure tone threshold: normal hearing has a threshold of 0 to 20 dB; mild hearing loss from 20 to 40 dB; moderate hearing loss from 40 to 60 dB; severe hearing loss from 60 to 80 dB; and profound hearing loss greater than 80 dB. Characteristic patterns that vary with the type of hearing loss are seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The audiogram of a child with a conductive hearing loss shows normal bone-conducted pure tone thresholds and abnormal air-conducted pure tone thresholds. The difference in the air- and bone-conducted thresholds is termed the",
"      <span class=\"nowrap\">",
"       air/bone",
"      </span>",
"      gap.",
"     </li>",
"     <li>",
"      The audiogram of a child with sensorineural hearing loss shows both air- and bone-conducted pure tone thresholds that are outside of the normal range. Unilateral sensorineural hearing loss usually suggests an inner ear disorder.",
"     </li>",
"     <li>",
"      Audiograms of children with hereditary hearing loss have a characteristic U-shape, with better hearing in the high and low frequencies than in the middle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Speech audiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speech audiometry consists of two parts: the speech threshold (also called the speech reception threshold) and the word discrimination score. The speech threshold is the softest level at which a child can correctly repeat 50 percent of presented \"spondee\" words. Spondee words are usually two-syllable words such as airplane, armchair, or pancake. The speech threshold is recorded in decibels and serves as a cross-check for the pure tone air-conduction thresholds. The speech threshold is typically equal to the pure tone air-conduction average, &plusmn;10 dB. The pure tone average is the average decibel score at 500, 1000, and 2000 Hz.",
"   </p>",
"   <p>",
"    The word discrimination score is the percentage of phonetically balanced words that a child can correctly repeat at a given sensation level. Testing is typically performed at 40 dB above the child's speech threshold. This discrimination score serves two purposes: it can establish the prognosis for the use of a hearing aid, and it helps determine the site of the lesion. A poor discrimination score usually indicates significant neural degeneration; these individuals may not be good candidates for hearing aids because the aid will amplify sound but may not permit the child to understand what is being said.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Behavioral testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children are not able to cooperate with pure tone or speech audiometry testing as described above. Their hearing is assessed using behavioral methods in conjunction with other tests, such as acoustic impedance testing, otoacoustic emissions, or auditory brainstem responses, as discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Behavioral observation audiometry &mdash; Behavioral observation audiometry (BOA) is used to examine auditory function in infants younger than six to eight months, children with multiple handicaps, or adults who are not able to cooperate for other types of testing. Live voice, warbled tones, or narrow-band noises are presented in a sound field environment to elicit reflexive and orienting responses to auditory stimuli. The responses can include head or limb reflex, whole-body startle, sucking, eye blinking, raising of the eyebrows, or cessation of certain behaviors, such as movement or sucking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Responses to stimuli are not reinforced.",
"      <br/>",
"      <br/>",
"      Behavioral observation is a subjective measure of hearing ability and does not provide ear-specific or frequency-specific information. It is best used in conjunction with objective methods. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Impedance testing'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Electrophysiology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Visual reinforcement audiometry &mdash; Visual reinforcement audiometry (VRA) is used to evaluate the hearing of infants and young children from about six months of age through the second year. Sound stimuli (live voice and tones) are presented in the sound field and via insert earphones. The child is visually rewarded with lighted and animated toys for turning his or her head toward the sound source. The child is conditioned to perform this task repeatedly. An experienced audiologist will use several lighted and animated toys and an intermittent reinforcement schedule to maintain the child's attention. Under ideal circumstances, complete ear-specific information for speech stimuli and interactive frequencies from 250 through 8000 Hz can be obtained.",
"     </li>",
"     <li>",
"      Play audiometry &mdash; Play audiometry is used to evaluate the hearing of children between the ages of 30 months and 5 years. Pure tones and speech information are presented via insert earphones. The child is taught to perform a simple task such as placing a block in a bucket or a peg on a pegboard each time a sound is heard. They are expected to perform the task over and over again when they hear the sound. The detection of speech sounds is determined by the child's ability to point to simple pictures when instructed by the audiologist.",
"      <br/>",
"      <br/>",
"      Speech understanding or speech discrimination scores are obtained in children who are able to perform the tests. Such tests use picture-pointing tasks for younger children and require reading skills for older children. Speech-understanding testing is used to evaluate the child's ability to hear and understand speech in quiet and noisy listening environments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Impedance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impedance audiometry (also known as immittance audiometry) evaluates the integrity and function of the middle ear system, including middle ear pressure, tympanic membrane mobility, eustachian tube function, continuity and mobility of the ossicles, and acoustic reflex thresholds. It is a quick, noninvasive test that requires little cooperation from the child.",
"   </p>",
"   <p>",
"    Full impedance audiometry encompasses tympanometry and stapedial reflex testing. Stapedial reflex testing is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Stapedial reflex'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tympanometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tympanometry measures the changes in the acoustic impedance of the middle ear system in response to changes in air pressure. As the pressure increases, the tympanic membrane is pushed medially; as negative pressure is placed, the tympanic membrane protrudes laterally. The point of maximum compliance of the middle ear is identified, indicating the status of air pressure in the middle ear.",
"   </p>",
"   <p>",
"    Five types of tympanograms can be seen (",
"    <a class=\"graphic graphic_figure graphicRef67750 \" href=\"mobipreview.htm?2/34/2595\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type A &mdash; Normal middle ear pressure",
"     </li>",
"     <li>",
"      Type B &mdash; Little or no mobility, suggestive of fluid behind the tympanic membrane or perforation",
"     </li>",
"     <li>",
"      Type C &mdash; Negative pressure in the middle ear, suggestive of a retracted tympanic membrane",
"     </li>",
"     <li>",
"      Type As &mdash; A very stiff middle ear system that can be caused by myringosclerosis or otosclerosis",
"     </li>",
"     <li>",
"      Type Ad &mdash; The highly compliant tympanic membrane seen in ossicular chain discontinuity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic tests of hearing do not require behavioral responses. They include auditory brainstem response, otoacoustic emissions, and stapedial reflex testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Brainstem response",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an infant fails a newborn hearing screen or if parents or the pediatric health care provider are concerned about hearing, an auditory brainstem response (ABR) test should be performed. This test is also known as auditory brainstem evoked response (ABER), brainstem evoked response audiometry (BERA), or brainstem auditory evoked response (BAER). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=see_link&amp;anchor=H8#H8\">",
"     \"Screening the newborn for hearing loss\", section on 'Auditory brainstem response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ABR is used in children who are younger than 30 months, developmentally delayed, intellectually disabled (mentally retarded), are otherwise difficult to test, or for confirmation of behavioral audiometric results. Sedation may be required for more accurate testing, since movement by the child can disrupt ABR results. ABR testing can be used to estimate auditory sensitivity, and it provides useful clinical information about the integrity of the eighth nerve pathway. It is not, however, a true test of hearing and should never be used alone or as a substitute for behavioral hearing testing.",
"   </p>",
"   <p>",
"    The ABR test uses click stimuli and tone burst stimuli from loud (80 or 90 dB) to soft (0 to 20 dB) to evoke responses from the auditory pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/19\">",
"     19",
"    </a>",
"    ]. These responses are recorded using electrodes placed on the head and ears of the child. A computer averages the responses, and the waveforms generated are compared to normative data.",
"   </p>",
"   <p>",
"    Delayed or absent waves suggest cochlear or neurologic deficits. Normal hearing or conductive hearing loss patterns can also be recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/11\">",
"     11",
"    </a>",
"    ]. Children with central hearing loss, also known as auditory neuropathy, have absent or severely distorted auditory brainstem responses with preserved otoacoustic emissions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Otoacoustic emissions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otoacoustic emission (OAE) tests are used in newborn hearing screening programs and to confirm sensorineural hearing loss. Normal OAE in conjunction with normal audiometry, in children who are 6 to 30 months old, can eliminate the need for ABR (which requires sedation). In addition, OAE testing has been used to monitor aminoglycoside-induced ototoxicity and to differentiate central from peripheral auditory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening the newborn for hearing loss\", section on 'Otoacoustic emissions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otoacoustic emissions are faint sounds produced by the electromobile motion of the outer hair cells of the cochlea in a healthy ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. These sounds are transmitted retrograde through the middle ear and the tympanic membrane and can be measured by a microphone sealed in the external auditory canal. The test is quick and noninvasive. The presence of OAE suggests normal cochlear function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Stapedial reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acoustic stapedius reflex (ASR) is the sound-evoked contraction of the stapedius muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/23\">",
"     23",
"    </a>",
"    ]. It is mediated by a neural network with afferent input from the auditory nerve and efferent output to the facial nerve. The central portion of the reflex pathway is comprised of several centers in the brain. ASR is used to evaluate retrocochlear pathology. An ear with a significant conductive hearing loss, however, will also demonstrate abnormal ASR. In this case, ASR is absent both when the ear with the conductive hearing loss is stimulated with sound and when it is tested for a stapedial response.",
"   </p>",
"   <p>",
"    The stapedius muscle in each ear normally responds to ipsilateral, contralateral, and binaural stimulation. The normal ASR threshold is 90 to 95 dB for tones and 70 to 75 dB for wideband noise. ASR thresholds are more elevated for wideband noise than for tones in ears with sensorineural hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of hearing loss is directed by the history, physical examination, and results of audiologic or electrophysiologic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Testing for congenital cytomegalovirus using urine or saliva, as well as targeted genetic testing, can determine the cause of hearing loss in a high percentage of newborns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Initial tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with newly diagnosed sensorineural hearing loss should have a urinalysis and electrocardiogram to evaluate for several rare disorders. The presence of hematuria or proteinuria suggests a diagnosis of Alport syndrome (hereditary nephritis) or branchiootorenal syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/25\">",
"     25",
"    </a>",
"    ]. The first symptoms of Jervell and Lange-Nielsen (JLN) syndrome, the autosomal recessive form of congenital long QT syndrome, may be syncope or sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/25\">",
"     25",
"    </a>",
"    ]. Beta blocker therapy and cardiac pacing can prevent these symptoms if the defect is detected early. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Congenital sensorineural deafness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ancillary evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that are considered, depending upon the history, physical examination, and results of audiologic and electrophysiologic tests, include tests for congenital infection (eg, syphilis, toxoplasmosis, cytomegalovirus), thyroid function, complete blood count with differential, serum glucose, autoimmune tests (erythrocyte sedimentation rate, anti-nuclear antibody [ANA], and rheumatoid factor [RF]), and ophthalmologic examination for retinitis pigmentosa and other ophthalmologic abnormalities (",
"    <a class=\"graphic graphic_table graphicRef77212 \" href=\"mobipreview.htm?5/26/5549\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/9,25-27\">",
"     9,25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA testing for mutations in the connexin 26 gene (CX26, also called gap junction protein beta 2 [GJB2]), may be performed for children with congenital sensorineural hearing loss, since it is the most common recessive genetic cause of sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Additional genetic testing may be helpful in patients with specific clinical findings, as indicated below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive or sporadic SNHL (particularly if bilateral and profound) and only one CX26 mutation: test for mutations in connexin 30 (CX30, also called gap junction protein beta 6, GJB6).",
"     </li>",
"     <li>",
"      History of exposure to aminoglycoside antibiotics: test for mutations in mitochondrial 12S rRNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enlarged vestibular aqueduct: test for mutations in solute carrier family 26, member 4 (SLC26A4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Auditory",
"      <span class=\"nowrap\">",
"       neuropathy/dyssynchrony:",
"      </span>",
"      test for mutations in otoferlin (OTOF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Congenital hearing loss and vestibular problems: test for mutations in myosin VI (MYO6), myosin VIIA (MYO7A), and transmembrane inner-ear-expressed gene (TMIE).",
"     </li>",
"     <li>",
"      Onset of hearing loss at or after 15 years of age and vestibular problems: test for mutations in cochlin (COCH) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Later-onset, low-frequency hearing loss: test for mutations in Wolfram syndrome gene (WFS1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several tools for genetic screening for nonsyndromic sensorineural hearing loss have been developed in addition to single gene targeted testing. Microarray-based testing (&ldquo;gene chips&rdquo;) allow for testing a number of genes at once [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/39\">",
"     39",
"    </a>",
"    ]. These chips allow for cost-effective genetic testing and enable more accurate genetic counseling by providing early, efficient, and definitive diagnosis. This technology is in rapid evolution. At least two laboratories will have gene chips that test over 50 hearing loss genes available for clinical use by the end of 2012. These gene chips screen for genetic defects that may have subtle but important clinical phenotypes, such as Usher syndrome and Pendred syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RADIOLOGIC TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic imaging can help to clarify the cause of hearing loss in specific clinical situations. Plain radiographs are seldom useful. Computed tomography (CT) and magnetic resonance imaging (MRI) provide information about bony- and soft-tissue anatomy that can narrow the differential diagnosis in sensorineural hearing loss (SNHL) and may guide therapy in both SNHL and conductive hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In one series, CT or MRI abnormalities were detected in 39 percent of children with sensorineural or mixed hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/24\">",
"     24",
"    </a>",
"    ]. Imaging studies are generally requested by the otolaryngologist as part of advanced diagnostic testing, rather than by the primary care provider. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography of the temporal bone is useful in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/24,42-48\">",
"     24,42-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaluation of inner ear dysplasias",
"     </li>",
"     <li>",
"      Evaluation of trauma to the temporal bone",
"     </li>",
"     <li>",
"      Evaluation of congenital anomalies of, trauma to, or tumors of the middle ear and ossicular chain",
"     </li>",
"     <li>",
"      Evaluation of conductive hearing loss caused by external canal atresia, neoplasms, myringosclerosis, or cholesteatomas",
"     </li>",
"     <li>",
"      Documentation of anatomy of the middle or inner ear prior to surgery",
"     </li>",
"     <li>",
"      Preoperative evaluation for cochlear implantation",
"     </li>",
"     <li>",
"      Recurrent meningitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective analysis of 116 children with bilateral sensorineural hearing loss who had CT of the temporal bone and internal auditory meatus found abnormalities in 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/46\">",
"     46",
"    </a>",
"    ]. CT scan abnormalities were more common in children with progressive hearing loss than in those with non-progressive disease",
"    <span class=\"nowrap\">",
"     (6/9",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     26/103),",
"    </span>",
"    profound hearing loss than those with less severe hearing loss",
"    <span class=\"nowrap\">",
"     (17/38",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     15/75),",
"    </span>",
"    and craniofacial abnormalities than those without craniofacial abnormalities",
"    <span class=\"nowrap\">",
"     (9/16",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     24/100).",
"    </span>",
"    CT abnormalities were found in 7 percent of children who did not have progressive hearing loss, profound hearing loss, or craniofacial abnormalities. For these reasons, the authors recommended radiologic investigation of all children with sensorineural hearing loss.",
"   </p>",
"   <p>",
"    In another retrospective review, 90 children with sensorineural hearing loss underwent CT scan of the temporal bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/24\">",
"     24",
"    </a>",
"    ]. Radiologic abnormalities were present in 33 (37 percent); large vestibular aqueduct, lateral semicircular canal dysplasia, and cochlear dysplasia were the most common findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is indicated in children with neurofibromatosis type 2 or progressive hearing loss who have a normal CT scan or in whom audiologic testing reveals retrocochlear pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/24,41,43\">",
"     24,41,43",
"    </a>",
"    ]. It is also useful in children with auditory neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/49\">",
"     49",
"    </a>",
"    ]. Contrast-enhanced MRI is preferred when inflammatory and neoplastic disorders are suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/45\">",
"     45",
"    </a>",
"    ]. Gadolinium-enhanced MRI can detect labyrinthitis, which is useful in predicting SNHL in children with bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/50\">",
"     50",
"    </a>",
"    ]. MRI may also be used prior to cochlear implantation for assessment of the eighth cranial nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44344/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early identification and effective treatment of hearing loss improves language, communication, and cognitive skills. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with hearing loss should have a complete history, physical examination, and formal audiologic testing to determine the type and etiology of hearing loss (",
"      <a class=\"graphic graphic_table graphicRef53903 \" href=\"mobipreview.htm?4/62/5101\">",
"       table 1",
"      </a>",
"      ) and the optimal treatment plan. Infants with hearing loss should be evaluated by an otolaryngologist and have at least one examination to assess visual acuity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history include conditions associated with hearing loss (eg, congenital infection; prematurity; hyperbilirubinemia; meningitis; recurrent otitis media; exposure to ototoxic drugs, noise, or barotrauma; kidney disease; cardiac dysrhythmia; or decreased visual acuity), family history of hearing loss or retinitis pigmentosa, the onset and progression of hearing loss, associated symptoms (pain, drainage from the ear, tinnitus, vertigo, disequilibrium), and history of previous ear surgery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination should include measurement of growth parameters and assessment of general appearance (looking for manifestations of syndromic hearing loss) (",
"      <a class=\"graphic graphic_table graphicRef66758 \" href=\"mobipreview.htm?12/21/12638\">",
"       table 2",
"      </a>",
"      ). Examination of the ear should include inspection of the preauricular area and outer ear (for pits or sinuses, pinna size and shape, patency of the external auditory canal), inspection of the tympanic membrane (for perforation, scarring, middle ear fluid), and pneumatic otoscopy. In older children and adolescents, hearing status can be assessed in the office using 256 Hz and 512 Hz tuning forks. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Objective audiologic screening is recommended for all newborns, and periodically for children between 4 and 11 years of age. Abnormal hearing screening tests should be followed up with formal audiology. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Office audiology screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43225?source=see_link&amp;anchor=H9#H9\">",
"       \"Screening tests in children and adolescents\", section on 'Hearing screen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Formal audiologic assessment is performed by an audiologist in a soundproof environment and provides detailed information about hearing ability. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Formal audiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrophysiologic tests of hearing, which do not require behavioral responses, include auditory brainstem response, otoacoustic emissions, and stapedial reflex testing. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Electrophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory evaluation of hearing loss is directed by the history, physical examination, and results of audiologic or electrophysiologic testing. All children with newly diagnosed sensorineural hearing loss should have a urinalysis, an electrocardiogram, and an eye examination. Other tests that may be indicated are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef77212 \" href=\"mobipreview.htm?5/26/5549\">",
"       table 4",
"      </a>",
"      ). A high percentage of hearing loss that presents in infancy and early childhood is genetic. Single gene and simultaneous gene (&ldquo;gene chips&rdquo;) testing is becoming increasingly available. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic imaging can help to clarify the cause of hearing loss in specific clinical situations. Imaging studies are generally requested by the otolaryngologist as part of advanced diagnostic testing, rather than by the primary care provider. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Radiologic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/1\">",
"      Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics 1998; 102:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/2\">",
"      Downs MP, Yoshinaga-Itano C. The efficacy of early identification and intervention for children with hearing impairment. Pediatr Clin North Am 1999; 46:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/3\">",
"      Yoshinaga-Itano C. Benefits of early intervention for children with hearing loss. Otolaryngol Clin North Am 1999; 32:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/4\">",
"      Watkin P, McCann D, Law C, et al. Language ability in children with permanent hearing impairment: the influence of early management and family participation. Pediatrics 2007; 120:e694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/5\">",
"      Vohr B, Jodoin-Krauzyk J, Tucker R, et al. Early language outcomes of early-identified infants with permanent hearing loss at 12 to 16 months of age. Pediatrics 2008; 122:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/6\">",
"      Pimperton H, Kennedy CR. The impact of early identification of permanent childhood hearing impairment on speech and language outcomes. Arch Dis Child 2012; 97:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/7\">",
"      American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. Pediatrics 2007; 120:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/8\">",
"      Kral A, O'Donoghue GM. Profound deafness in childhood. N Engl J Med 2010; 363:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/9\">",
"      Sharma A, Ruscetta MN, Chi DH. Ophthalmologic findings in children with sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2009; 135:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/10\">",
"      Preslan MW, Novak A. Baltimore Vision Screening Project. Phase 2. Ophthalmology 1998; 105:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/11\">",
"      Pickett BP, Ahlstrom K. Clinical evaluation of the hearing-impaired infant. Otolaryngol Clin North Am 1999; 32:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/12\">",
"      Ohlms LA, Chen AY, Stewart MG, Franklin DJ. Establishing the etiology of childhood hearing loss. Otolaryngol Head Neck Surg 1999; 120:159.",
"     </a>",
"    </li>",
"    <li>",
"     Recommendations for preventive pediatric health care. Pediatrics 2007; 120:1376. practice.aap.org/content.aspx?aid=1599 (Accessed on September 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/14\">",
"      Harlor AD Jr, Bower C, Committee on Practice and Ambulatory Medicine, Section on Otolaryngology-Head and Neck Surgery. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics 2009; 124:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/15\">",
"      American Academy of Family Physicians, American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Pediatrics Subcommittee on Otitis Media With Effusion. Otitis media with effusion. Pediatrics 2004; 113:1412.",
"     </a>",
"    </li>",
"    <li>",
"     Gerber SE. The handbook of pediatric audiology, Gallaudet University Press, Washington, DC 1996.",
"    </li>",
"    <li>",
"     Northern JL, Downs MP. Hearing in children, 4th ed, Williams &amp; Wilkins, Baltimore 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/18\">",
"      Jerger J. Clinical experience with impedance audiometry. Arch Otolaryngol 1970; 92:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/19\">",
"      Smith RJ, Bale JF Jr, White KR. Sensorineural hearing loss in children. Lancet 2005; 365:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/20\">",
"      Deltenre P, Mansbach AL, Bozet C, et al. Auditory neuropathy with preserved cochlear microphonics and secondary loss of otoacoustic emissions. Audiology 1999; 38:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/21\">",
"      Stavroulaki P, Apostolopoulos N, Dinopoulou D, et al. Otoacoustic emissions--an approach for monitoring aminoglycoside induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 1999; 50:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/22\">",
"      Kemp DT. Evidence of mechanical nonlinearity and frequency selective wave amplification in the cochlea. Arch Otorhinolaryngol 1979; 224:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/23\">",
"      Margolis RH. Detection of hearing impairment with the acoustic stapedius reflex. Ear Hear 1993; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/24\">",
"      Mafong DD, Shin EJ, Lalwani AK. Use of laboratory evaluation and radiologic imaging in the diagnostic evaluation of children with sensorineural hearing loss. Laryngoscope 2002; 112:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/25\">",
"      Wilson C, Roberts A, Stephens D. Aetiological investigation of sensorineural hearing loss in children. Arch Dis Child 2005; 90:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/26\">",
"      Billings KR, Kenna MA. Causes of pediatric sensorineural hearing loss: yesterday and today. Arch Otolaryngol Head Neck Surg 1999; 125:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/27\">",
"      Johnston DR, Curry JM, Newborough B, et al. Ophthalmologic disorders in children with syndromic and nonsyndromic hearing loss. Arch Otolaryngol Head Neck Surg 2010; 136:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/28\">",
"      McCabe ER, McCabe LL. State-of-the-art for DNA technology in newborn screening. Acta Paediatr Suppl 1999; 88:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/29\">",
"      Frei K, Ramsebner R, Lucas T, et al. GJB2 mutations in hearing impairment: identification of a broad clinical spectrum for improved genetic counseling. Laryngoscope 2005; 115:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/30\">",
"      Rehm HL. A genetic approach to the child with sensorineural hearing loss. Semin Perinatol 2005; 29:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/31\">",
"      Yaeger D, McCallum J, Lewis K, et al. Outcomes of clinical examination and genetic testing of 500 individuals with hearing loss evaluated through a genetics of hearing loss clinic. Am J Med Genet A 2006; 140:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/32\">",
"      Zhao H, Li R, Wang Q, et al. Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. Am J Hum Genet 2004; 74:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/33\">",
"      Campbell C, Cucci RA, Prasad S, et al. Pendred syndrome, DFNB4, and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. Hum Mutat 2001; 17:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/34\">",
"      Rodr&iacute;guez-Ballesteros M, del Castillo FJ, Mart&iacute;n Y, et al. Auditory neuropathy in patients carrying mutations in the otoferlin gene (OTOF). Hum Mutat 2003; 22:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/35\">",
"      Varga R, Kelley PM, Keats BJ, et al. Non-syndromic recessive auditory neuropathy is the result of mutations in the otoferlin (OTOF) gene. J Med Genet 2003; 40:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/36\">",
"      Robertson NG, Hamaker SA, Patriub V, et al. Subcellular localisation, secretion, and post-translational processing of normal cochlin, and of mutants causing the sensorineural deafness and vestibular disorder, DFNA9. J Med Genet 2003; 40:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/37\">",
"      Bespalova IN, Van Camp G, Bom SJ, et al. Mutations in the Wolfram syndrome 1 gene (WFS1) are a common cause of low frequency sensorineural hearing loss. Hum Mol Genet 2001; 10:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/38\">",
"      Young TL, Ives E, Lynch E, et al. Non-syndromic progressive hearing loss DFNA38 is caused by heterozygous missense mutation in the Wolfram syndrome gene WFS1. Hum Mol Genet 2001; 10:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/39\">",
"      Gardner P, Oitmaa E, Messner A, et al. Simultaneous multigene mutation detection in patients with sensorineural hearing loss through a novel diagnostic microarray: a new approach for newborn screening follow-up. Pediatrics 2006; 118:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/40\">",
"      Shearer AE, DeLuca AP, Hildebrand MS, et al. Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A 2010; 107:21104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/41\">",
"      Tomaski SM, Grundfast KM. A stepwise approach to the diagnosis and treatment of hereditary hearing loss. Pediatr Clin North Am 1999; 46:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/42\">",
"      Phillips RR, Phelps PD. Imaging in congenital deafness. Arch Dis Child 1991; 66:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/43\">",
"      Simons JP, Mandell DL, Arjmand EM. Computed tomography and magnetic resonance imaging in pediatric unilateral and asymmetric sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2006; 132:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/44\">",
"      Weissman JL. Hearing loss. Radiology 1996; 199:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/45\">",
"      Lowe LH, V&eacute;zina LG. Sensorineural hearing loss in children. Radiographics 1997; 17:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/46\">",
"      Bamiou DE, Phelps P, Sirimanna T. Temporal bone computed tomography findings in bilateral sensorineural hearing loss. Arch Dis Child 2000; 82:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/47\">",
"      Bamiou DE, Savy L, O'Mahoney C, et al. Unilateral sensorineural hearing loss and its aetiology in childhood: the contribution of computerised tomography in aetiological diagnosis and management. Int J Pediatr Otorhinolaryngol 1999; 51:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/48\">",
"      Robson CD. Congenital hearing impairment. Pediatr Radiol 2006; 36:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/49\">",
"      Licameli G, Kenna MA. Is computed tomography (CT) or magnetic resonance imaging (MRI) more useful in the evaluation of pediatric sensorineural hearing loss? Laryngoscope 2010; 120:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44344/abstract/50\">",
"      Kopelovich JC, Germiller JA, Laury AM, et al. Early prediction of postmeningitic hearing loss in children using magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 2011; 137:441.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6297 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44344=[""].join("\n");
var outline_f43_19_44344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ear examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Office hearing tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OFFICE AUDIOLOGY SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FORMAL AUDIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pure tone audiometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Speech audiometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Behavioral testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Impedance testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tympanometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ELECTROPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Brainstem response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Otoacoustic emissions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Stapedial reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Initial tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ancillary evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RADIOLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6297|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/5/41043\" title=\"figure 1\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/34/2595\" title=\"figure 2\">",
"      Tympanogram classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/62/5101\" title=\"table 1\">",
"      Causes of hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/21/12638\" title=\"table 2\">",
"      Syndromes with hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/32/32268\" title=\"table 3\">",
"      Test results in hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/26/5549\" title=\"table 4\">",
"      Evaluation hearing loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24280?source=related_link\">",
"      Congenital and acquired goiter in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12055?source=related_link\">",
"      Congenital anomalies of the ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/18/8487?source=related_link\">",
"      Craniosynostosis syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=related_link\">",
"      Screening the newborn for hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_19_44345="Infections involving cardiac implantable electronic devices";
var content_f43_19_44345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infections involving cardiac implantable electronic devices",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44345/contributors\">",
"     Adolf W Karchmer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44345/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44345/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44345/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/19/44345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/19/44345/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/19/44345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like any other foreign bodies, implanted cardiac devices (ie, pacemakers and implantable cardioverter-defibrillators [ICDs]) can become infected. The presentation, consequences, and treatment of device infections vary according to the location and extent of infection and the clinical characteristics of the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Device infections are generally considered in two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pocket infections &mdash; The term pocket infection is used when the infection involves the subcutaneous pocket containing the device and the subcutaneous segment of the leads (ie, not the transvenous segment). In some cases, part of the device or lead erodes through the overlying skin. Such an erosion can occur without overt evidence of infection, but there is inescapable contamination of the site and these cases are managed as pocket infections.",
"     </li>",
"     <li>",
"      Deeper infection &mdash; This term is used when the infection involves the transvenous portion of the lead, usually with associated bacteremia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endovascular infection. Deep infection can occur with or without involvement of the generator pocket and can include device-related endocarditis in which there may be vegetations on the intracardiac portion of the lead.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, device infections may be classified by the mode of infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary infections, in which the device",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pocket itself is the source of infection, usually due to contamination at the time of implant.",
"     </li>",
"     <li>",
"      Secondary infection, in which the leads (and then sometimes the device and the pocket) are seeded due to bacteremia from a different source.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presentation and management of cardiac pacemaker and ICD infections will be discussed here. Noninfectious complications of pacemakers and ICDs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link\">",
"     \"Pacing system malfunction: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38295?source=see_link\">",
"     \"Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7878123\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of cardiac device infection is difficult to determine due to the lack of a comprehensive registry or mandatory reporting. A range of values has been reported in a number of observational series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In a review of 21 studies of pacemaker and ICD recipients with variable follow-up, the rate of infections ranged from 0.8 to 5.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 8303 pacemaker insertions for which antistaphylococcal periprocedure prophylaxis was routinely administered, pacemaker-associated infection occurred in 468 patients (5.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/2\">",
"       2",
"      </a>",
"      ]. The infection in 44 of these patients (0.5 percent of all insertions) was consistent with a precise definition of pacemaker endocarditis.",
"     </li>",
"     <li>",
"      In a population-based survey in France in 1999, the annual age- and sex-standardized incidence of pacemaker endocarditis was 550 cases per one million pacemaker recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3\">",
"       3",
"      </a>",
"      ]. Among 33 patients with definite pacemaker lead endocarditis, 16 also had valvular involvement (10 tricuspid and six aortic or mitral valves). Twelve other patients had valvular endocarditis without evidence of pacemaker involvement.",
"     </li>",
"     <li>",
"      In a retrospective cohort study of residents of Olmsted County, Minnesota between 1975 and 2004, 1524 cardiac device patients were identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/4\">",
"       4",
"      </a>",
"      ]. Over 7578 device-years of follow-up, the incidence of definite device infection was 1.9 per 1000 device-years. The incidence of infection was significantly higher for ICDs than for pacemakers (8.9 versus 1.0 per 1000 device-years).",
"     </li>",
"     <li>",
"      In a prospective study of 6319 consecutive recipients of pacemakers or ICDs in 44 medical centers in France during 2000, during 12 months of follow-up the rate of infection was 0.68 per 100 patients (95% CI, 047 to 0.89), and infection plus erosions were noted in 1.19 per 100 patients (95% CI, 0.92 to 1.46) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors and comorbid conditions have been associated with pacemaker and ICD infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,7-10\">",
"     3,7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent manipulation of the device, particularly elective secondary manipulations such as generator exchange",
"     </li>",
"     <li>",
"      Temporary pacing prior to permanent device placement",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Underlying malignancy",
"     </li>",
"     <li>",
"      Operator inexperience",
"     </li>",
"     <li>",
"      Advanced patient age",
"     </li>",
"     <li>",
"      Prior treatment with anticoagulants or glucocorticoids",
"     </li>",
"     <li>",
"      Generator replacement",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Renal dysfunction (glomerular filtration rate &lt;60",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recent manipulation of the device (eg, newly implanted device, device revision, or generator change) is the most clearly identified and causal of these risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In registry of 6319 consecutive patients undergoing implantation of a pacemaker or ICD, device-related infections occurred over the ensuing 12 months in 0.56 percent of initial implantations and 0.99 percent of non-denovo implantations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/8\">",
"     8",
"    </a>",
"    ]. The other risk factors for device infection noted were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever within 24 hours of implantation (adjusted OR 5.8)",
"     </li>",
"     <li>",
"      Use of temporary pacing prior to implantation (adjusted OR 2.5)",
"     </li>",
"     <li>",
"      Early reintervention (adjusted OR 15.0)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for permanent pacemaker infection were further analyzed in a case-control study in which 29 such patients were matched with 58 uninfected controls with a permanent pacemaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/11\">",
"     11",
"    </a>",
"    ]. On multivariable analysis, only two independent risk factors for infection were identified: long-term glucocorticoid therapy (odds ratio 13.9); and the presence of more than two pacing leads compared with two pacing leads (odds ratio 5.4). On the other hand, antibiotic prophylaxis prior to pacemaker implantation had a protective effect (odds ratio 0.09).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pocket infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative contamination of the pacemaker pocket with skin flora appears to be the most common source of subcutaneous infection. This was illustrated in a prospective study including 103 patients undergoing elective pacemaker implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/12\">",
"     12",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Swab specimens, obtained from the pulse generator pocket upon completion of and immediately prior to suturing the pocket, yielded bacteria from 48 and 37 percent of specimens, respectively; the organisms were predominantly coagulase-negative staphylococci.",
"     </li>",
"     <li>",
"      Five patients (4.8 percent) developed subsequent pacemaker infections. Staphylococcus schleiferi (a coagulase-negative species) caused three of these infections at 4,16, and 29 months after implantation. Based upon molecular typing, the S. schleiferi isolates recovered at surgery and at the time of the infection appeared identical.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the infection rate was markedly lower than the periprocedure contamination rate, this study suggests that perioperative contamination can result in a delayed onset infection.",
"   </p>",
"   <p>",
"    Erosion through the skin of a pacemaker or ICD system component (eg, the device itself or the subcutaneous portion of a lead) can be a portal for contamination that leads to infection. Alternatively, such erosions can occur as a secondary phenomenon due to pressure that develops on the overlying skin from a preexisting infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Deeper infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the intravascular component of a pacemaker or ICD system occurs primarily on the intracardiac portion of the lead along the right atrium, the tricuspid valve, or the right ventricular contact point. These infections may track intravascularly from infection of a subcutaneous pacer component or may arise by bacteremic seeding from a remote site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/2,13-15\">",
"     2,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The host response to the intravenous lead can provide protection from late bacteremic seeding. Approximately one week after placement, the portion of the lead in contact with the vein intima becomes partially incorporated into the vein wall by connective tissue and an endothelial covering. Fibrous tissue proliferation at some sites in the vena cava and right atrium results in a fibrotic attachment of the pacing lead to these points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. While these changes make subsequent extraction of pacing leads difficult (see",
"    <a class=\"local\" href=\"#H25\">",
"     'System removal'",
"    </a>",
"    below), the endothelial covering may protect the lead against the adherence of bacteria and subsequent infection during episodes of bacteremia.",
"   </p>",
"   <p>",
"    Epicardial electrodes may be infected at the cardiac attachment point as a result of intraoperative contamination or less likely by spread of infection along pacing electrodes from an infected pulse generator pocket.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. aureus and coagulase-negative staphylococci, often S. epidermidis, cause 65 to 75 percent of generator pocket infections and up to 89 percent of device-related endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/5,11,18,19\">",
"     5,11,18,19",
"    </a>",
"    ]. Episodes arising within two weeks of implantation are more likely to be due to S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Seeding of the device from systemic bacteremia primarily occurs with S. aureus infections. Among staphylococci causing device infection, methicillin resistance should be assumed until tests demonstrate methicillin susceptibility. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Gram-positive bacteremia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Streptococci, Corynebacterium spp, Propionibacterium acnes, gram-negative bacilli, and Candida spp have caused occasional pulse generator pocket infections and device-related endocarditis.",
"   </p>",
"   <p>",
"    Among 162 episodes of precisely defined pacemaker endocarditis, coagulase-negative staphylococci caused 61 percent and S. aureus caused 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/2,3,13,14\">",
"     2,3,13,14",
"    </a>",
"    ]. Methicillin resistance was common among all of these staphylococci. Polymicrobial infection occurred in 18 patients, and cultures were negative in seven (",
"    <a class=\"graphic graphic_table graphicRef55942 \" href=\"mobipreview.htm?34/45/35547\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a series of 44 episodes of device endocarditis between 1991 and 2003, the number of infections due to coagulase-negative staphylococci, S. aureus, fungi, gram-negative bacilli, and P. acnes was 18, 18, 3, 2 and 1, respectively. One case was polymicrobial. Among the three fungal infections, there were two cases of A. fumigatus and one case of C. albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/22\">",
"     22",
"    </a>",
"    ]. Blood cultures were positive in 34 episodes (77 percent) and in 10 patients with negative blood cultures, six had received prior antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SYSTEMIC INFECTIONS IN PATIENTS WITH CARDIAC DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic infections have the potential to seed implanted cardiac devices. The likelihood of such involvement varies according to the nature of the infection and the pathogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gram-positive bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with implanted cardiac devices, S. aureus bacteremia is associated with a relatively high rate of device infection, morbidity, and mortality. A review of S. aureus bacteremia in patients with implanted pacemakers or ICDs yielded several important observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with bacteremia within the year following device placement or manipulation, infection of the generator pocket was often confirmed by culture even in the absence of local signs and symptoms of pocket infection.",
"     </li>",
"     <li>",
"      Among 12 patients with S. aureus bacteremia within the year after device placement, infection of the device occurred in nine patients. The devices themselves were the source of the bacteremia in six and were seeded hematogenously in three.",
"     </li>",
"     <li>",
"      Among 21 patients with bacteremia one year or more after device placement, hematogenous seeding of the device occurred in six.",
"     </li>",
"     <li>",
"      Among 27 patients with S. aureus bacteremia not arising from the device itself, the device was infected hematogenously in nine and the device status was indeterminant in nine others. The device was definitively spared in only nine patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study, 62 patients with either an implanted pacemaker or an ICD experienced S. aureus bacteremia; this occurred greater than one year after implantation in 63 percent of cases. Of these patients, 22 (37 percent) had device infection. Bacteremia presenting &lt;3 months after implantation was associated with generator pocket infection. Among patients with bacteremia &gt;1 year after device placement, 30 percent had device infection, almost all of which was device-related endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, patients with implanted cardiac devices who develop S. aureus bacteremia require aggressive treatment, often including explantation of the system (see",
"    <a class=\"local\" href=\"#H25\">",
"     'System removal'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gram-negative bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative organisms do not often seed cardiac devices. This was illustrated in a retrospective study of 49 patients with gram-negative bacteremia and either a permanent pacemaker or an ICD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/25\">",
"     25",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three patients had evidence of infection within the device pocket.",
"     </li>",
"     <li>",
"      None of the patients developed typical pacemaker endocarditis.",
"     </li>",
"     <li>",
"      Among 34 patients in whom the device was not explanted, two patients had recurrent bacteremia at a median follow up of two years, both of whom had sources other than the retained device for the second infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, gram-negative bacteremia from sources other than the cardiac device rarely seed the device pocket or leads. In the absence of evidence of pocket infection or device-related endocarditis, such patients can be treated without explantation of the device or leads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/15,25\">",
"     15,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Valve infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Device infection can occur alone",
"    <strong>",
"     or",
"    </strong>",
"    in association with concomitant valvular infection. In addition, the device may remain uninfected in patients with valvular endocarditis. The frequency of and microbiologic differences between these types of infections were illustrated in the French survey cited above in which detailed TEE was performed in 45 patients with pacemakers and endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pacemaker endocarditis was noted in 33 patients, 16 of whom had concurrent heart valve involvement. Seventy percent of these infections were caused by staphylococci.",
"     </li>",
"     <li>",
"      The other 12 patients had valve infection without evident involvement of the pacemaker. The involved pathogens included staphylococci (42 percent), streptococci or enterococci (50 percent), and Actinobacillus actinomycetemcomitans, a HACEK infection (8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, in a study of 44 episodes of device related infective endocarditis, 38 patients had device infection with or without valve leaflet involvement, and six had infection confined to the aortic or mitral valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, device infections can either be superficial, involving the pulse generator pocket and the subcutaneous portion of the leads, or deep, infecting the transvenous lead or epicardial electrode. Pocket infections are the most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/7,19\">",
"     7,19",
"    </a>",
"    ]. However, infection of the pocket can extend to the intravascular lead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Generator pocket infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections involving the generator pocket typically develop soon after device implantation or battery exchange. These infections present as acute or subacute wound infections with swelling, erythema, pain, and occasionally drainage through a dehisced incision. These early onset infections may be associated with fever and systemic symptoms and may be accompanied by bacteremia. However, fever and systemic symptoms are often absent when infection is localized to the generator pocket [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pocket infections can also arise many months after implantation due to a chronic, smoldering infection related to contamination at the time of implant. Delayed erosion of the leads",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    device through the skin may result from a chronic infection, but may also be related to weight loss, a superficial pocket, or trauma at the site (",
"    <a class=\"graphic graphic_picture graphicRef74725 \" href=\"mobipreview.htm?42/29/43472\">",
"     picture 1",
"    </a>",
"    ). These later infections may have minimal local inflammatory changes and may lack systemic symptoms. The sole major finding may be the point of erosion itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Deeper infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deeper infection may involve epicardial or transvenous electrodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Transvenous electrodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of transvenous electrodes primarily involves the intracardiac lead and is essentially a right-sided endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13\">",
"     13",
"    </a>",
"    ]. Co-existent left-sided endocarditis is occasionally seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. Rarely, left-sided endocarditis occurs with malpositioning of the lead into the left ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation is usually subacute, although occasional patients present with sepsis syndrome and shock. Among the more common presenting features in patients with device-related endocarditis are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &mdash; 84 to 100 percent.",
"     </li>",
"     <li>",
"      Chills &mdash; 75 to 84 percent.",
"     </li>",
"     <li>",
"      Pulmonary abnormalities &mdash; Symptoms or radiologic findings consistent with pneumonia, bronchitis, lung abscess, or embolism occur in 20 to 45 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. In particular, pulmonary embolism has occurred in 11 to 40 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,13,14,18,22\">",
"       3,13,14,18,22",
"      </a>",
"      ]. Metastatic seeding of bone, joints, liver and spleen may be noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tricuspid abnormalities &mdash; Tricuspid regurgitation develops in about 25 percent of patients, while tricuspid stenosis resulting from an obstructing vegetation is occasionally encountered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/2,28\">",
"       2,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5558?source=see_link&amp;anchor=H2#H2\">",
"       \"Tricuspid stenosis: Clinical features, diagnosis, and percutaneous tricuspid balloon valvotomy\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presentation of endocarditis varies with the time after device manipulation. Approximately one-third of cases of device-related endocarditis occur within three to six months of a device manipulation (eg, initial implantation or generator change) and are promptly recognized because of the concurrence of systemic symptoms and associated generator pocket infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,13,14\">",
"     3,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, two-thirds of these episodes present more than three to six months after device manipulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,13,14\">",
"     3,13,14",
"    </a>",
"    ]. In this late onset group, the average interval from device manipulation to the onset of endocarditis symptoms is 25 months, and the symptoms are often protean, resulting in a delayed diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Epicardial electrodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;When epicardial electrodes are infected, fever, constitutional symptoms, and signs of pericarditis or mediastinitis can occur. Bacteremia arises commonly in patients with infection at the site of attachment to the epicardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generator pocket infection is generally suspected based upon the clinical presentation, while device-related endocarditis presents in a more subtle fashion and is often more difficult to diagnose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Generator infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of generator infection should be considered when there is inflammation over the implanted device or erosion of the device through the skin. The diagnosis is confirmed by culture of material aspirated from the inflamed site using sterile technique. Percutaneous aspiration of the generator pocket is not recommended. When pockets are explored surgically, culture of tissue is more sensitive than a swab culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Device-related endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term device-related endocarditis is applied to infection of one or more pacemaker or ICD leads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13\">",
"     13",
"    </a>",
"    ]. It primarily involves the intracardiac portion lead and is essentially a right-sided endocarditis. Up to one-half of patients also have echocardiographic or intraoperative evidence of a vegetation on a valve (usually the tricuspid valve) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. The time course and manifestations of device-related endocarditis were discussed in the preceding section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6682428\">",
"    <span class=\"h3\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected device-related endocarditis should have at least two sets of blood cultures obtained before antibiotics are initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"     29",
"    </a>",
"    ]. Generator pocket tissue and lead tips should be cultured when devices are explanted. Unless removed at cardiac surgery or through an incision other than the pocket, lead tip culture results should be interpreted in the context of the overall data. Positive tip cultures when leads are extracted through the pocket may reflect pocket infection or contamination and not lead-related endocarditis. Erroneous assessment of positive cultures can result in unduly long antibiotic therapy and related toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/22,29\">",
"     22,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6682442\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that the Duke criteria for the diagnosis of infective endocarditis (IE) (",
"    <a class=\"graphic graphic_table graphicRef73023 graphicRef53004 \" href=\"mobipreview.htm?42/47/43773\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/30\">",
"     30",
"    </a>",
"    ] can be used with modifications to facilitate the diagnosis of device-related endocarditis. If generator pocket abnormalities and pulmonary emboli had been added as major Duke criteria, the clinical diagnosis of definite device-related endocarditis would have been made in 86 percent of pathologically confirmed cases, and no confirmed case would have been rejected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31094?source=see_link&amp;anchor=H5#H5\">",
"     \"Infective endocarditis: Historical and Duke criteria\", section on 'Duke criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using the modified Duke criteria to evaluate a patient with suspected device-related endocarditis, a transesophageal echocardiogram (TEE) should be obtained in those patients with a nondiagnostic transthoracic echocardiogram (TTE). The superiority of TEE in detection of vegetations has been demonstrated in a number of studies; TEE identified vegetations on the tricuspid valve or device lead in 90 to 96 percent of patients with endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13,14,18,31\">",
"     13,14,18,31",
"    </a>",
"    ] compared with only 22 to 43 percent with TTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/2,13,14,18,22,31\">",
"     2,13,14,18,22,31",
"    </a>",
"    ]. It is important to keep in mind that fibrous material and stranding is not uncommonly seen when TEE is performed on patients with chronic leads, in the absence of endocarditis. The TEE also allows assessment of the lead in the proximal superior vena cava. The TTE may, however, be important for defining prognostic features such as ventricular function and dysfunction, pericardial effusion and pulmonary vascular blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Device infection can occur alone or be associated with concomitant valvular infection; in addition, the device may remain uninfected in patients with valvular endocarditis. These different infections are associated with differences in microbiology, as described above, and in clinical features. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Systemic infections in patients with cardiac devices'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical and microbiological features were illustrated in the French survey cited previously, in which detailed TEE was performed in 45 patients with pacemakers and endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pacemaker endocarditis was noted in 33 patients, 16 of whom had concurrent heart valve involvement (10 tricuspid, six aortic or mitral valves). Multiple pacemaker implantations were common in these patients; the median time from recent implantation to infection was 0.75 years (range 0.01 to 8 years). Seventy percent of these infections were caused by staphylococci.",
"     </li>",
"     <li>",
"      The other 12 patients had valve infection without evidence of pacemaker involvement. Multiple implantations were infrequent; the median interval between the last implantation and infection was 2.2 years (range 0.08 to 7.2). The pathogens infecting these patients were staphylococci (42 percent) and less virulent organisms more typically associated with endocarditis (58 percent) such as streptococci, enterococci, and HACEK.",
"     </li>",
"     <li>",
"      Among 11 patients with pacemakers and prosthetic valves in place, infection involved only the prosthetic valves in 5, the pacemaker alone in 1, native valves alone in 3 patients, native valve and pacemaker and prosthetic valve and pacemaker in 1 each.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22061995\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined positron emission tomography (PET) with fluorodesoxyglucose marked by fluorine-18 (18F-FDG) and computed tomography (CT) can be useful in detection and localization of infection. PET technology may be useful for distinguishing soft tissue infection (which overlies the generator) from generator infection, and can define infection along the subcutaneous course of electronic leads and within the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. PET depends upon uptake of 18F-FDG by inflammatory cells at the site of infection. This raises questions about its utility in patients with leukopenia or after prolonged administration of antibiotics. Data are insufficient to allow precise estimates of sensitivity and specificity in assessing suspected electronic device infection. Although it is premature to suggest 18F-FDG PET be routinely applied in the evaluation of suspected infection of electronic devices, the technology may be useful in selected diagnostic dilemmas. Studies suggest that judicious use of this technology may alter management strategy. In one study, if 18F-FDG PET findings had been used in deciding management, device removal in 6 of 42 patients (15 percent) might have obviated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other entities to consider in the differential diagnosis of device-related endocarditis include septic jugular thrombophlebitis and lower extremity or pelvic vein thrombophlebitis, all with pulmonary embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2055?source=see_link\">",
"     \"Suppurative (septic) thrombophlebitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=see_link\">",
"     \"Septic pelvic thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dental Panorex films and contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) of the neck and upper thorax could be considered to evaluate the possibility of septic jugular thrombophlebitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of an infected device, regardless of the involved component, generally requires removal of the entire system and administration of antimicrobials directed at the responsible organism(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/19,20,22,26,29,31,34\">",
"     19,20,22,26,29,31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three general components of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antibiotics",
"     </li>",
"     <li>",
"      Explantation of the device and usually the leads",
"     </li>",
"     <li>",
"      Reimplantation of a new system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The details of the therapeutic approach depend upon the extent of infection, the pathogen, and the patient's clinical profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of an antibiotic regimen is based upon the extent of infection and which, if any, organism is identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy is empiric, with intravenous antibiotics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In cases where a cardiac pacemaker or ICD pocket infection is suspected, antibiotics including antistaphylococcal coverage should be initiated (after obtaining at least two independent blood cultures). Because of the high incidence of methicillin resistance with S. aureus and S. epidermidis, initial therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      is reasonable. High dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      is a possible alternative to vancomycin for either initial empiric or definitive therapy of staphylococcal infection involving an implantable electronic cardiac device. Evidence supporting the alternative use of daptomycin include one study of 25 cases of device-related infection, in which high dose daptomycin (mean 8.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [range 6.4-10.7",
"      <span class=\"nowrap\">",
"       mg/kg])",
"      </span>",
"      resulted in cure or improvement in 23 of 25 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/35\">",
"       35",
"      </a>",
"      ]. Devices were explanted in 22 patients; 2 patients with retained devices remained bacteremic during therapy. Caution is required when treating S. aureus",
"      <em>",
"      </em>",
"      infections with daptomycin in the setting of vancomycin failure; S. aureus non-susceptibility to daptomycin has been observed when the organism has persisted in spite of vancomycin therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/36\">",
"       36",
"      </a>",
"      ]. Therefore, repeat testing of the S. aureus isolate associated with vancomycin failure should be performed to ensure susceptibility to daptomycin.",
"     </li>",
"     <li>",
"      In cases with evidence of deeper infection (eg, device-related endocarditis, or pocket infection with bacteremia), we recommend the initiation of intravenous antibiotics as for bacterial endocarditis. At a minimum, therapy should include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or a comparable parenteral agent effective against methicillin-resistant staphylococci. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"       \"Antimicrobial therapy of native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a causative organism is identified through blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wound cultures, the antibiotic regimen can be tailored as appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy depends upon the nature of the infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infections limited to the pocket and subcutaneous tissue (blood cultures are sterile and transesophageal echocardiography is negative), we recommend continuation of antibiotics for 10 to 14 days after explantation of the infected system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/19,29\">",
"       19,29",
"      </a>",
"      ]. For device infection due to erosion of the generator in the absence of local inflammation, a 7 to 10 day course of antibiotics after explantation may be sufficient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"       29",
"      </a>",
"      ]. The timing of the transition to oral antibiotics depends on several factors, including the presence (or absence) of systemic signs of infection, the severity of the local infection, and the urgency of implanting a new system.",
"     </li>",
"     <li>",
"      Patients with device-related endocarditis or with a generator pocket infection and bacteremia should receive a full course of parenteral antibiotics as would be given to treat endocarditis caused by the implicated organism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/7,14,37\">",
"       7,14,37",
"      </a>",
"      ]. As noted above, approximately one-half of patients with pacemaker endocarditis have concurrent valvular infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,22\">",
"       3,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"       \"Antimicrobial therapy of native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     System removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an infection is known to involve a pacemaker or ICD, removal of the device and leads is usually recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/19,22,29\">",
"     19,22,29",
"    </a>",
"    ]. In some cases (eg, bacteremia from an unknown source), an initial strategy of aggressive intravenous antibiotic therapy with initial retention of the device",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leads can be considered. It should be noted, however, that when device infection is highly likely, antibiotic therapy without device removal entails increased risk. Among 415 patients with infection of implanted electronic cardiac devices, of which 67 percent were caused by staphylococci, a multi-variate analysis adjusted for high-risk device removal indicated that patients who did not undergo device removal experienced a sevenfold (HR 6.97 [95% CI 1.36-35.6]) increase in 30 day mortality. Although device removal can be associated with complications and thus risk of death, immediate device removal (in contrast with removal after failure of antimicrobial therapy or no removal) was associated with a threefold (HR 0.35 [95% CI 0.16-0.75]) reduction in mortality at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/38\">",
"     38",
"    </a>",
"    ]. Another large study demonstrated that device removal during the index hospitalization was associated with decreased mortality at one year; failure to pursue device removal incurred increased mortality risk at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decisions regarding device and lead removal are based upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The location and extent of infection (eg, pocket infection, device-related endocarditis, or bacteremia of unknown source in a pacemaker or ICD patient)",
"     </li>",
"     <li>",
"      The pathogen, with lead removal being particularly important in infections due to S. aureus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13,23,24,40\">",
"       13,23,24,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk for bradyarrhythmias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tachyarrhythmias if the device is removed. Plans should be made for managing these issues until reimplantation of a new device is considered safe.",
"     </li>",
"     <li>",
"      The age of the system, since leads that have been in place for more than one to two years are more difficult to extract. On the other hand, systems that have been in place for longer periods of time are less likely to be secondarily infected due to bacteremia.",
"     </li>",
"     <li>",
"      The patient's overall condition and prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Explantation of the pacemaker or ICD generator (ie, not the leads) is a relatively straightforward and safe procedure, and can be done as soon as the diagnosis is confirmed. Following explantation of the device, the infected subcutaneous pocket is usually packed open and treated with local wound care. In some cases, if the pocket is not purulent, primary closure can be performed after extensive debridement. In general, the system should be explanted as soon as is feasible after the diagnosis of infection is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Device removal indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The device should be removed whenever there is evidence that the device pocket or leads are infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"     29",
"    </a>",
"    ]. This occurs in two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pocket infection with or without associated bacteremia",
"     </li>",
"     <li>",
"      Lead infection, which is essentially synonymous with device-related endocarditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Device explantation is also recommended for patients with bacteremia even in the absence of evidence of device infection in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      S. aureus bacteremia without an alternative source.",
"     </li>",
"     <li>",
"      Bacteremia due to any pathogen that persists or recurs without an alternative source despite appropriate antibiotic therapy.",
"     </li>",
"     <li>",
"      When patients undergo valve replacement or repair for infective endocarditis (eliminates a source for potential relapse)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Situations in which retention of the device may be attempted include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with bacteremia from a defined source other than the device (including valvular infection) if the following conditions are met: there is no clinical or TEE evidence of lead infection; there is no evidence of pocket infection; and the device has not been recently manipulated. Such patients may be treated with antibiotics for the bacteremic disease and then observed for relapse. Subsequent unexplained relapse suggests device infection and a need to extract the system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3,24,29\">",
"       3,24,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with superficial cellulitis at the incision in whom the infection does not appear to extend into the generator pocket may be treated without device removal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"       29",
"      </a>",
"      ]. However, this distinction is often difficult to make, and patients managed with device retention require close observation. In general, device retention is usually reserved for patients in whom device removal poses significant risks (eg, patients with major comorbidities, long standing devices, or who require continuous pacemaker support). Aggressive antibiotic therapy should be administered with this approach. If there is evidence of recurrent, persistent, or progressive infection despite appropriate intravenous antibiotic therapy, the system should be removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional issues related to device removal, including the various techniques used and the interim cardiac management of device-dependent patients, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30921?source=see_link\">",
"     \"Cardiac implantable electronic device lead removal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Lead extraction indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the challenges related to lead extraction, we favor lead removal in most cases that require device explantation, particularly the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Device-related endocarditis, since failure to remove an infected lead is associated with a high rate of relapsed infection and mortality even with a full course of appropriate antibiotic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13-15,20,21,26,34,40\">",
"       13-15,20,21,26,34,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pocket infections requiring device explantation, even without evidence of deeper infection. In most cases, the risks of recurrent infection outweigh the risks of extraction. Leads that have been in place for more than two years can still be safely removed by experienced operators in most cases, although the risks are higher than with newer leads. The decision to attempt lead removal is individualized in these cases. As discussed above, ICD leads tend to have more extensive adhesions than pacemaker leads; thus, the type of leads can impact this decision.",
"     </li>",
"     <li>",
"      Patients without overt evidence of pocket infection or endocarditis, but with S. aureus bacteremia that requires generator explantation.",
"     </li>",
"     <li>",
"      Patients without overt evidence of pocket infection or endocarditis, but with S. aureus bacteremia or bacteremia with any pathogen that persists or recurs despite appropriate antibiotic therapy without an alternative source.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases of pocket infection without bacteremia or endocarditis, lead retention may be considered for patients in whom severe comorbidities or extenuating circumstances exist (eg, extreme frailty) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/41\">",
"     41",
"    </a>",
"    ]. Some individuals with lead infection or endocarditis are managed without device and lead explantation; these are usually extremely frail patients with limited life expectancy or patients refusing device removal. In such cases, however, long-term oral suppressive antibiotics are usually the alternative to lead removal. These patients are at high risk of failure with relapse and increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/22,29\">",
"     22,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assiduous aseptic technique in a controlled environment should be used when implanting pacemakers or ICDs and when changing pulse generator units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"     29",
"    </a>",
"    ]. Since operator experience affects outcome, the procedure should generally be performed by an individual who has done many device implantations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H5#H5\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Operator characteristics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Prophylaxis at implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic antibiotic prophylaxis is generally advised for surgical implantation of foreign devices. Microbiologic and epidemiologic data suggest that contamination with skin flora is responsible for a significant proportion of device infections.",
"   </p>",
"   <p>",
"    Evidence of benefit comes from a meta-analysis of seven randomized trials (only one of which was double-blind and placebo-controlled) that evaluated antibiotic prophylaxis administered immediately before permanent pacemaker implantation in 2023 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/44\">",
"     44",
"    </a>",
"    ]. A consistent protective effect was noted for short-term pocket infection, skin erosion, or septicemia (odds ratio 0.26, 95% CI 0.10 to 0.66) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/44\">",
"     44",
"    </a>",
"    ]. The systemic antimicrobials used were antistaphylococcal penicillins and first generation cephalosporins, although the regimens varied considerably between trials.",
"   </p>",
"   <p>",
"    A low rate of infection with prophylaxis was also noted in a subsequent review of 852 patients who underwent placement of a new pacemaker or replacement of a pulse generator and received 2 g of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    intravenously over 20 minutes before beginning the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/45\">",
"     45",
"    </a>",
"    ]. Nine patients (1 percent) had minor infectious complications within the first two months. Six patients (0.7 percent) had major infectious complications between 12 and 55 months.",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis reduces risk for device infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/8,11,46\">",
"     8,11,46",
"    </a>",
"    ]. A randomized trial demonstrated that patients randomized to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    prior to device implantation had a lower infection rate than those who received placebo (0.6 versus 3.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, the American Heart Association recommends prophylaxis with antistaphylococcal antimicrobial drugs at the time pacemakers are implanted or generator units exchanged. The dosing regimens are similar to those used for cardiac surgery (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 to 2 g IV within 60 minutes of surgical incision or, if there is concern about cephalosporin allergy or colonization by methicillin-resistant staphylococci,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    1 g IV 90 to 120 minutes of incision) (",
"    <a class=\"graphic graphic_table graphicRef76499 \" href=\"mobipreview.htm?27/33/28188\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29,47\">",
"     29,47",
"    </a>",
"    ]. For patients who cannot tolerate beta-lactam antibiotics or vancomycin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    are alternatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antibiotic selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient bacteremia associated with mucosal trauma rarely results in pacemaker or ICD infection. As a result, prophylaxis at times of mucosal trauma or manipulation is not recommended for patients with pacemakers or ICDs unless they have another significant independent indication for endocarditis prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29,48\">",
"     29,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to infections of implanted cardiac pacemakers and implantable cardioverter-defibrillators.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of device infections is low. Although some series have reported an incidence as high as 5.7 percent, population-based studies suggest rates below 1 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staphylococcus species account for up to 75 percent of pocket infections and 89 percent of device-related endocarditis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of device infections usually includes fever and constitutional symptoms, particularly for deeper infections. Pocket infections may present with local findings at the site of the device in addition to systemic symptoms, especially if the infection develops in the first few months after implantation. Pocket infections in older devices often have less prominent local and systemic symptoms. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with suspected pocket infection or device-related endocarditis, we recommend that intravenous antibiotics that cover methicillin-resistant staphylococci be started empirically (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), following collection of at least two independent blood cultures. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric therapy should be continued until culture results are available. Once a pathogen is identified, the antibiotic regimen should be tailored as appropriate. For patients with uncomplicated pocket infection and no blood stream infection, antibiotic therapy should be continued for at least 14 days after device removal. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with device-related endocarditis (definite or implied by",
"      <span class=\"nowrap\">",
"       persistent/relapsed",
"      </span>",
"      bacteremia) or with a generator pocket infection and bacteremia, following complete device removal parenteral antibiotic therapy be continued for the full course that would be given to treat endocarditis caused by the implicated organism (at least 4 to 6 weeks). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"       \"Antimicrobial therapy of native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     System removal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a documented infection involving the pocket or device leads, we recommend explantation of the device and all associated leads (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ), in association with appropriate antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'System removal'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30921?source=see_link\">",
"       \"Cardiac implantable electronic device lead removal\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with recurrent or persistent S. aureus bacteremia without an alternative source, we suggest the system be explanted even in the absence of evidence of pocket infection or device-related endocarditis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with bacteremia due to any pathogen that persists or recurs without an alternative source despite appropriate antibiotic therapy, we suggest the device be explanted even in the absence of evidence of pocket infection or device-related endocarditis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'System removal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10842662\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the time of device implantation or generator exchange, we recommend prophylaxis with antistaphylococcal antimicrobial drugs. (",
"      <a class=\"graphic graphic_table graphicRef76499 \" href=\"mobipreview.htm?27/33/28188\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Antibiotic selection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With regard to routine endocarditis prophylaxis (eg, for dental work), patients with a cardiac pacemaker or an ICD are considered to be at low risk for endocarditis. For these patients, we suggest that routine antibiotic prophylaxis for endocarditis",
"      <strong>",
"       not",
"      </strong>",
"      be given (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/1\">",
"      Baddour LM, Cha YM, Wilson WR. Clinical practice. Infections of cardiovascular implantable electronic devices. N Engl J Med 2012; 367:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/2\">",
"      Arber N, Pras E, Copperman Y, et al. Pacemaker endocarditis. Report of 44 cases and review of the literature. Medicine (Baltimore) 1994; 73:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/3\">",
"      Duval X, Selton-Suty C, Alla F, et al. Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection. Clin Infect Dis 2004; 39:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/4\">",
"      Uslan DZ, Sohail MR, St Sauver JL, et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med 2007; 167:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/5\">",
"      Smith PN, Vidaillet HJ, Hayes JJ, et al. Infections with nonthoracotomy implantable cardioverter defibrillators: can these be prevented? Endotak Lead Clinical Investigators. Pacing Clin Electrophysiol 1998; 21:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/6\">",
"      Lai KK, Fontecchio SA. Infections associated with implantable cardioverter defibrillators placed transvenously and via thoracotomies: epidemiology, infection control, and management. Clin Infect Dis 1998; 27:265.",
"     </a>",
"    </li>",
"    <li>",
"     Eggimann P, Waldvogel F. Pacemaker and defibrillator infections. In: Infections Associated with Indwelling Medical Devices, Waldvogel FA, Bisno AL (Eds), American Society for Microbiology Press, Washington, DC 2000. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/8\">",
"      Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007; 116:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/9\">",
"      Bloom H, Heeke B, Leon A, et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol 2006; 29:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/10\">",
"      Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart 2009; 95:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/11\">",
"      Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007; 45:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/12\">",
"      Da Costa A, Leli&egrave;vre H, Kirkorian G, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation 1998; 97:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/13\">",
"      Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation 1997; 95:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/14\">",
"      Cacoub P, Leprince P, Nataf P, et al. Pacemaker infective endocarditis. Am J Cardiol 1998; 82:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/15\">",
"      Camus C, Leport C, Raffi F, et al. Sustained bacteremia in 26 patients with a permanent endocardial pacemaker: assessment of wire removal. Clin Infect Dis 1993; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/16\">",
"      Cox JN. Pathology of cardiac pacemakers and central catheters. Curr Top Pathol 1994; 86:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/17\">",
"      Spittell PC, Hayes DL. Venous complications after insertion of a transvenous pacemaker. Mayo Clin Proc 1992; 67:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/18\">",
"      Massoure PL, Reuter S, Lafitte S, et al. Pacemaker endocarditis: clinical features and management of 60 consecutive cases. Pacing Clin Electrophysiol 2007; 30:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/19\">",
"      Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007; 49:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/20\">",
"      Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin North Am 2002; 16:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/21\">",
"      Lewis AB, Hayes DL, Holmes DR Jr, et al. Update on infections involving permanent pacemakers. Characterization and management. J Thorac Cardiovasc Surg 1985; 89:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/22\">",
"      Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc 2008; 83:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/23\">",
"      Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/24\">",
"      Uslan DZ, Dowsley TF, Sohail MR, et al. Cardiovascular implantable electronic device infection in patients with Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol 2010; 33:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/25\">",
"      Uslan DZ, Sohail MR, Friedman PA, et al. Frequency of permanent pacemaker or implantable cardioverter-defibrillator infection in patients with gram-negative bacteremia. Clin Infect Dis 2006; 43:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/26\">",
"      Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med 2000; 133:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/27\">",
"      Schulze MR, Ostermaier R, Franke Y, et al. Images in cardiovascular medicine. Aortic endocarditis caused by inadvertent left ventricular pacemaker lead placement. Circulation 2005; 112:e361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/28\">",
"      Voet JG, Vandekerckhove YR, Muyldermans LL, et al. Pacemaker lead infection: report of three cases and review of the literature. Heart 1999; 81:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/29\">",
"      Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010; 121:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/30\">",
"      Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/31\">",
"      Victor F, De Place C, Camus C, et al. Pacemaker lead infection: echocardiographic features, management, and outcome. Heart 1999; 81:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/32\">",
"      Sarrazin JF, Philippon F, Tessier M, et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol 2012; 59:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/33\">",
"      Brinker J. Imaging for infected cardiac implantable electronic devices: a new trick for your pet. J Am Coll Cardiol 2012; 59:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/34\">",
"      Baddour LM, Bettmann MA, Bolger AF, et al. Nonvalvular cardiovascular device-related infections. Circulation 2003; 108:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/35\">",
"      Durante-Mangoni E, Casillo R, Bernardo M, et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 2012; 54:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/36\">",
"      van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-na&iuml;ve patient--a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30:603.",
"     </a>",
"    </li>",
"    <li>",
"     Baddour LM, Wilson WR. Infections of prosthetic valves and intravascular devices. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.1022.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/38\">",
"      Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 2011; 8:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/39\">",
"      Athan E, Chu VH, Tattevin P, et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA 2012; 307:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/40\">",
"      Bracke FA, Meijer A, van Gelder LM. Pacemaker lead complications: when is extraction appropriate and what can we learn from published data? Heart 2001; 85:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/41\">",
"      Samuels LE, Samuels FL, Kaufman MS, et al. Management of infected implantable cardiac defibrillators. Ann Thorac Surg 1997; 64:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/42\">",
"      Harcombe AA, Newell SA, Ludman PF, et al. Late complications following permanent pacemaker implantation or elective unit replacement. Heart 1998; 80:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/43\">",
"      Byrd CL, Wilkoff BL, Love CJ, et al. Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute. Pacing Clin Electrophysiol 1999; 22:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/44\">",
"      Da Costa A, Kirkorian G, Cucherat M, et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation 1998; 97:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/45\">",
"      Bertaglia E, Zerbo F, Zardo S, et al. Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of long-term infective complications. Pacing Clin Electrophysiol 2006; 29:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/46\">",
"      de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/19/44345/abstract/47\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2012; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2146 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44345=[""].join("\n");
var outline_f43_19_44345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7878123\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pocket infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Deeper infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SYSTEMIC INFECTIONS IN PATIENTS WITH CARDIAC DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gram-positive bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gram-negative bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Valve infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Generator pocket infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Deeper infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Transvenous electrodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Epicardial electrodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Generator infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Device-related endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6682428\">",
"      - Cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6682442\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22061995\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      System removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Device removal indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Lead extraction indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Prophylaxis at implantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      System removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10842662\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2146|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/29/43472\" title=\"picture 1\">",
"      Pacemaker pocket erosion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/45/35547\" title=\"table 1\">",
"      Microbiology pacemaker endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/26/9644\" title=\"table 2A\">",
"      Duke criteria for IE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/31/6653\" title=\"table 2B\">",
"      Duke criteria for IE II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/33/28188\" title=\"table 3\">",
"      Antimicrobial prophylaxis for cardiac surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30921?source=related_link\">",
"      Cardiac implantable electronic device lead removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=related_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=related_link\">",
"      Septic pelvic thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5558?source=related_link\">",
"      Tricuspid stenosis: Clinical features, diagnosis, and percutaneous tricuspid balloon valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38295?source=related_link\">",
"      Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_19_44346="Keratoacanthoma - face";
var content_f43_19_44346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55042%7EDERM%2F81629%7EDERM%2F59593%7EDERM%2F73408%7EDERM%2F52368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55042%7EDERM%2F81629%7EDERM%2F59593%7EDERM%2F73408%7EDERM%2F52368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A crateriform nodule with central hyperkeratosis is on the helix of the ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A keratoacanthoma with a characteristic central accumulation of keratin is present on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A dome-shaped nodule with keratotic core is present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A nodule with central hyperkeratosis is present on the lower eyelid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44346=[""].join("\n");
var outline_f43_19_44346=null;
var title_f43_19_44347="Systemic infections associated with skin lesions";
var content_f43_19_44347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected systemic infections associated with skin lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Bartonellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichiosis (rash in &lt;5 percent human granulocytotropic anaplasmosis; 20 to 30 percent in human monocytotropic ehrlichiosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroviral infections (eg, Coxsackie, other)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dengue, chikungunya (and other arboviruses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonococcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV (acute, primary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leishmaniasis, visceral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptospirosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melioidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningococcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ratbite fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relapsing fever (louse-borne and tick-borne)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsial infections (many)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trypanosomiasis, African",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tularemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhoid and paratyphoid (enteric) fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     List is not comprehensive. Many arboviruses (arthropod-borne viruses) can have an associated rash.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44347=[""].join("\n");
var outline_f43_19_44347=null;
var title_f43_19_44348="Subclasses of Type 0 superficial tumors";
var content_f43_19_44348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paris classification system of superficial neoplastic lesions of the gastrointestinal tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paris classification system of superficial neoplastic lesions of the esophagus, stomach, and colon. Type 0-I lesions are polypoid (protruded or pendunculated); type 0-II lesions are nonpolypoid and may be slightly elevated (IIa), flat (IIb), or slightly depressed (IIc); type 0-III lesions are excavated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from: The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58(6 suppl):S3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44348=[""].join("\n");
var outline_f43_19_44348=null;
var title_f43_19_44349="TNM stage mesothelioma";
var content_f43_19_44349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for diffuse malignant pleural mesothelioma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor limited to the ipsilateral parietal pleura with or without mediastinal pleura and with or without diaphragmatic pleural involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        No involvement of the visceral pleura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor also involving the visceral pleura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        T2",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Tumor involving each of the ipsilateral pleural surface (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Involvement of diaphragmatic muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Extension of tumor from visceral pleura into the underlying pulmonary parenchyma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Locally advanced but potentially resectable tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Involvement of the endothoracic fascia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Extension into the mediastinal fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Nontransmural involvement of the pericardium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Locally advanced technically unresectable tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Direct transdiaphragmatic extension of tumor to the peritoneum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Direct extension of tumor to the contralateral pleura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Direct extension of tumor to mediastinal organs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Direct extension of tumor into the spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion or tumor involving the myocardium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2",
"       </td>",
"       <td colspan=\"3\">",
"        Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes including the ipsilateral internal mammary and peridiaphragmatic nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N3",
"       </td>",
"       <td colspan=\"3\">",
"        Metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral supraclavicular lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MI",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IA",
"       </td>",
"       <td>",
"        T1a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IB",
"       </td>",
"       <td>",
"        T1b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Stage III",
"       </td>",
"       <td>",
"        T1, T2",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1, T2",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0, N1, N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Stage IV",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44349=[""].join("\n");
var outline_f43_19_44349=null;
var title_f43_19_44350="Drug therapy in type 2 diabetes";
var content_f43_19_44350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Metabolic effects of drug therapy in type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 358px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean changes in body weight (top) and fasting plasma insulin concentrations (bottom) over six years in patients with type 2 diabetes mellitus in the primary diet failure group who were allocated to therapy with insulin (red), sulfonylurea (blue), or, only in obese subjects, metformin (green). Left panels show data from nonobese patients, right panels show data from obese patients. Metformin did not increase weight or raise plasma insulin. To convert plasma insulin values to &micro;U/mL divide by 6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998; 128:165.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44350=[""].join("\n");
var outline_f43_19_44350=null;
var title_f43_19_44351="Circulating hot water ablation";
var content_f43_19_44351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circulating hot water system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hot water circulated throughout an abnormal cavity is able to make contact with all surfaces, potentially providing better endometrial ablation than with a nonconforming system, such as a balloon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_19_44351=[""].join("\n");
var outline_f43_19_44351=null;
